

October 04, 2017

To,  
The Secretary,  
The BSE Limited  
Phiroze Jeejeebhoy Towers  
Dalal Street, Fort  
Mumbai 400001


Dear Sir,

**Sub.: Submission of Company's 23<sup>rd</sup> Annual Report [FY 2016-17].**  
**Ref: BSE Scrip Code: 531625**

With reference to the above mentioned subject please find enclosed herewith the 23<sup>rd</sup> Annual Report [FY 2016-17] of our company for your kind information and record.

Thanking you,  
Yours truly,

For Sangam Health Care Product Limited




G S R Murthy  
Compliance Officer

## DECLARATION

I, A Bala Gopal, Managing Director of Ms Sangam Health Care Product Limited [Script Code 531625] do hereby declare that pursuant to the provisions of Regulations 33 & 52 of SEBI (Listing Obligations and Disclosure Requirements) Amendment Regulations, 2016, the Audit Report on the Annual Audited Financial results of the Company for the financial year ended 31<sup>st</sup> March, 2017 does not contain any modified opinion by the Statutory Auditors of the Company.

For Sangam Health Care Product Limited



A Bala Gopal  
Managing Director



**SANGAM HEALTH CARE  
PRODUCTS LIMITED**

*Disposable Medical Devices  
An ISO 9001:2008 Company*

**23rd ANNUAL REPORT  
2016-17**

Sl.	Contents	Page Nos.
1.	Corporate Information	02
2.	Notice	03
3.	Directors' Report	10
4.	Management Discussion and Analysis report	20
5.	Auditor's Report	24
6.	Secretarial Audit Report	32
7.	Report on Corporate Governance	36
8.	Certificate on Compliance of Corporate Governance	48
9.	Balance Sheet	58
10.	Statement of Profit & Loss	59
11.	Cash Flow Statement	60
12.	Notes forming part of the Financial statements	61
13.	Attendance Slip and Proxy Form	78

### **GREEN INITIATIVE**

The Ministry of Corporate Affairs (MCA) has taken a "Green Initiative in the Corporate Governance" by allowing paperless compliances by the Companies Act. As per the Section 101 read with Rule 18 of Companies (Management and Administration) Rules, 2014 of Companies Act, 2013. A member of Company can receive notice in electronic mode via email. Your Company has decided to join the MCA in its environment friendly initiative.

Henceforth, the Company proposes to send documents such as Notice of the General Meetings, Annual Report and other communication to its shareholders via electronic mode to the registered e-mail addresses of shareholders. To support this green initiative of the Government in full measure, shareholders are requested to register/update their latest e-mail addresses with their Depository Participant (D.P.) with whom they are having Demat A/c or send the same to the Company via e-mail at: [sangamlisting@gmail.com](mailto:sangamlisting@gmail.com)

We solicit your valuable co-operation and support in our endeavors to contribute our bit to the environment.

## CORPORATE INFORMATION

### BOARD OF DIRECTORS

#### Name of Director

Mr. Bala Gopal Addepally  
Mr. Lingaraj Shantalingappa Patil  
Mr. Basawaraj Nagabusappa Sajjan  
Mrs. Padma Ghanakota  
Mr. Khushwant Singh

#### Designation

Managing Director & Chairman  
Director  
Director  
Director  
Independent Director

### C.F.O.

V. Satish Kumar

### Compliance Officer

G.S.R. Murthy

### Auditors

M/s. Jayant & Sadashiv (FRN: 001297S)  
Chartered Accountants  
404-405, Sanatana Eternal  
3-6-108/1, Liberty Road  
Himayatnagar,  
Hyderabad-500029.

### Bankers

State Bank of Hyderabad  
Commercial Branch,  
Secunderabad

State Bank of Mysore  
IFB, Ameerpet Branch,  
Hyderabad.

### Registered Office

205 & 206, Amarchand Sharma Complex,  
S P Road, Secunderabad-2  
Phone # 040-27719551, 27718252  
Email: samgamlisting@gmail.com

### Share Transfer Agents

M/s. XL SOFTECH SYSTEMS LTD.,  
3, Sagar Society, Road No.2,  
Banjara Hills, Hyderabad  
Phone # 040-23545913/14/15  
Email: xlfield@rediffmail.com  
xlfield@gmail.com

### Factory :

Survey No.182, Yellampet Village,  
Medchal Mandal, RR District, Telangana.

## NOTICE

NOTICE is hereby given that the 23<sup>rd</sup> Annual General Meeting (AGM) of the Members of **Sangam Health Care Products Ltd** (CIN: L24230TG1993PLC016731) will be held on Friday, 29<sup>th</sup> September, 2017 at 3.00 P.M. at 205 & 206, Amarchand Sharma Complex, S.P. Road , Secunderabad- 500002 Telangana, to transact the following business:

### ORDINARY BUSINESS:

1. To receive, consider and adopt the financial statements of the Company for the year ended 31<sup>st</sup> March, 2017 along with the reports of the Board of Directors and Auditors thereon.
2. To re-appoint Mr. Bala Gopal Addepalli (DIN: 01712903), who retires by rotation, and being eligible offers himself for the re-appointment.

To consider and if though fit, to pass, with or without modification(s), the following Resolution as an Ordinary Resolution:

**“RESOLVED THAT** pursuant to the provisions of Section 152 of the Companies Act, 2013, Mr. Bala Gopal Addepalli (DIN: 01712903), who retires by rotation at this meeting and being eligible has offered himself for re-appointment, be and is hereby re-appointed as a Director of the Company, liable to retire by rotation.”

3. Appointment of Statutory Auditors

To consider and if though fit, to pass, with or without modification(s), the following Resolution as an Ordinary Resolution:

**“RESOLVED THAT** pursuant to the Section 139,142 and other applicable provisions, if any, of the Companies Act, 2013 (the Act), and the Companies (Audit and Auditors) Rules, 2014 (including any statutory modification(s) or re-enactment thereof, for the time being in force), M/s K. R. Shekher, Chartered Accountants, Hyderabad (Firm's Registration No. 010828S), have confirmed their eligibility to be appointed as Auditors in terms of the provisions of Section 141 of the Act and the relevant Rules and offered themselves for re-appointment, be and are hereby re-appointed as the Statutory Auditors of the Company to hold office from the conclusion of this Annual General Meeting till the conclusion of the 28<sup>th</sup> Annual General Meeting of the Company, at such remuneration plus applicable taxes, out-of-pocket, traveling expenses etc., as may be mutually agreed between the Board of Directors of the Company and the said Auditors.

**RESOLVED FURTHER THAT** the Board of Directors of the Company, be and is hereby authorized to do all such acts, deeds, matters and things as may be considered necessary, desirable or expedient to give effect to this Resolution."

**SPECIAL BUSSINESS:**

4. Appointment of Mr. Rajesh Kakkera as Independent director

To consider and if thought fit, to pass the following resolution as an Ordinary Resolution:

**"RESOLVED THAT** pursuant to the provisions of Sections 149, 150, 152 read with Schedule IV and other applicable provisions, if any, of the Companies Act, 2013 ("the Act") and the Companies (Appointment and Qualification of Directors) Rules, 2014 (including any statutory modification(s) or re-enactment thereof, for the time being in force), and pursuant to the applicable provisions of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, including any modification or amendment thereof, Mr. Rajesh Kakkera (DIN: 7931218), who was recommended by the board to be appointed by the Board of Directors of the Company to appoint as Independent Dircetor in the ensuring Annual General Meeting, be and is hereby appointed as an Independent Director of the Company to hold office for a term upto five consecutive years commencing from September 29, 2017"

5. Appointment of Mr. Ramu Chaganti as Independent director

To consider and if thought fit, to pass the following resolution as an Ordinary Resolution:

**"RESOLVED THAT** pursuant to the provisions of Sections 149, 150, 152 read with Schedule IV and other applicable provisions, if any, of the Companies Act, 2013 ("the Act") and the Companies (Appointment and Qualification of Directors) Rules, 2014 (including any statutory modification(s) or re-enactment thereof, for the time being in force), and pursuant to the applicable provisions of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, including any modification or amendment thereof, Mr. Ramu Chaganti (DIN: 7931223), who was recommended by the board to be appointed by the Board of Directors of the Company to appoint as Independent Dircetor in the ensuring Annual General Meeting, be and is hereby appointed as an Independent Director of the Company to hold office for a term upto five consecutive years commencing from September 29, 2017"

6. Appointment of Mr. Madhavarao Mandalapu as Independent director

To consider and if thought fit, to pass the following resolution as an Ordinary Resolution:

**“RESOLVED THAT** pursuant to the provisions of Sections 149, 150, 152 read with Schedule IV and other applicable provisions, if any, of the Companies Act, 2013 (“the Act”) and the Companies (Appointment and Qualification of Directors) Rules, 2014 (including any statutory modification(s) or re-enactment thereof, for the time being in force), and pursuant to the applicable provisions of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, including any modification or amendment thereof, Mr. Madhavarao Mandalapu (DIN: 7931672), who was recommended by the board to be appointed by the Board of Directors of the Company to appoint as Independent Director in the ensuing Annual General Meeting, be and is hereby appointed as an Independent Director of the Company to hold office for a term upto five consecutive years commencing from September 29, 2017”

By Order of the Board  
**For Sangam Health Care Products Ltd,**

Bala Gopal Addepalli  
Chairman  
DIN:01712903

Place: Secunderabad  
Date: September 05, 2017

**NOTES:**

1. The statement pursuant to Section 102(1) of the Companies Act, 2013 in respect of the special business set out in the Notice and Secretarial Standard on General Meetings (SS-2), wherever applicable, is annexed hereto.
2. The register of members and share transfer books of the Company will be closed from September 23, 2017 to September 29, 2017 (both days inclusive) for the purpose of Annual General Meeting.
3. A MEMBER ENTITLED TO ATTEND AND VOTE AT THE MEETING IS ENTITLED TO APPOINT A PROXY TO ATTEND AND VOTE ON BEHALF OF HIMSELF AND THE PROXY NEED NOT BE A MEMBER. THE PROXY FORMS SHOULD HOWEVER BE DEPOSITED AT THE REGISTERED OFFICE OF THE COMPANY NOT LATER THAN 48 HOURS BEFORE COMMENCEMENT OF THE MEETING.



4. A person can act as proxy on behalf of Members of not exceeding fifty (50) and holding in the aggregating not more than 10% of the total share capital of the company. In case a proxy is proposed to be appointed by a Member holding more than 10% of the total share capital of the company carrying voting rights then such proxy shall not act as proxy for any other person or shareholder. Proxies submitted on behalf of limited companies, societies, etc., must be supported by an appropriate resolution/ authority as applicable.
5. Members desiring any information are requested to write to the Company at its Registered Office, 205, 206, Amarchand Sharma Complex S.P. Road Secunderabad – 500002 at least one week prior to the date of the Annual General Meeting to enable the Management to keep the information ready.
6. The Register of Directors and Key Managerial Personnel and their shareholding, maintained under Section 170 of the Companies Act, 2013, will be available for inspection by the members at the AGM.
7. The Register of Contracts or Arrangements in which Directors are interested, maintained under Section 189 of the Companies Act, 2013, will be available for inspection by the members at the AGM.
8. Corporate Members intending to send their authorized representatives to attend the Meeting pursuant to Section 113 of the Companies Act, 2013 are requested to send to the Company, a certified copy of the relevant Board Resolution together with their respective specimen signatures authorizing their representative(s) to attend and vote on their behalf at the Meeting.
9. The annual report for the financial year 2016-17 has been sent through email to those members who have opted to receive electronic communication or who have registered their email addresses with the Company/depository participants. The annual report is also available on Company's website [sangamhealthcare.com](http://sangamhealthcare.com). The physical copy of the annual report has been sent to those members who have either opted for the same or have not registered their email addresses with the Company/depository participant. The members will be entitled to a physical copy of the annual report for the financial year 2016-17, free of cost, upon sending a request to the Company at 205,206, Amarchand Sharma Complex S.P. Road Secunderabad – 500002.
10. Members/Beneficial Owners/Proxies should bring the attendance slips duly filled in for attending the meeting.
11. Members/Beneficial Owners are requested to bring Annual Report with them for the Annual General Meeting. No copies of Annual Report will be distributed at the meeting.
12. Brief details of the directors re-appointed is annexed hereto as per the requirements of Regulation 36(3) of SEBI (LODR) Regulations, 2015.

13. The shares of the Company listed on BSE Limited but trading suspended. Company has not paid the listing fees to BSE.
14. The Company's Registrar and Transfer Agents for its Share Registry Work (Physical and Electronic) are **M/S. XL SOFTECH SYSTEMS LIMITED** having their Registered Office 3, Sagar Society, Road No.2, Banjara Hills, Hyderabad.

**15. VOTING THROUGH ELECTRONIC MEANS**

- i. Pursuant to Section 108 of Companies Act, 2013 read with Rule 20 of Companies (Management and Administration) Rules, 2014 as substituted by the Companies (Management and Administration) Amendment Rules, 2015, and Regulation 44 of the SEBI (LODR) Regulations, 2015 the company is pleased to provide Members' facility to exercise their right to vote at the 23<sup>rd</sup> Annual General Meeting (AGM) by electronic means and the business may be transacted through e-voting services provided by Central Depository Services Limited (CDSL). It may be noted that using of this e-voting facility is optional.
- ii. P. Surya Prakash, Senior Associate, R&A Associates, Company Secretary in Practice (ACS : 18803, C.P.No. 11142) has been appointed as the Scrutinizer for providing facility to the members of the Company to scrutinize the voting and remote e-voting process in a fair and transparent manner.
- iii. Voting rights shall be reckoned on the paid-up value of shares registered in the name of the member / beneficial owner (in case of electronic shareholding) as on the cut-off date i.e. September 23, 2017.
- iv. A person, whose name is recorded in the register of members or in the register of beneficial owners maintained by the depositories as on the cut-off date, i.e. September 23, 2017 only shall be entitled to avail the facility of remote e-voting and voting at AGM through polling paper.
- v. Any person who becomes a member of the Company after dispatch of the Notice of the Meeting and holding shares as on the cut-off date i.e. September 23, 2017, may obtain the *User ID* and *password* by writing to M/s. XL Softech Systems Limited at xfield@gmail.com or contact +91 40 23545913 / 14 / 15. However, if the person is already registered for remote voting then the existing user ID and password can be used for casting vote.
- vi. The facility for voting through polling paper shall be made available at the Meeting and the members attending the Meeting who have not cast their vote by remote e-voting shall be able to vote at the Meeting through polling paper.
- vii. The remote e-voting facility will be available during the following period:

COMMENCEMENT OF REMOTE E-VOTING	9.00 A.M. (IST) ON 26 <sup>TH</sup> SEPTEMBER, 2017
END OF REMOTE E-VOTING	5.00 P.M. (IST) ON 28 <sup>TH</sup> SEPTEMBER, 2017

The remote e-voting will not be allowed beyond the aforesaid date and time and the e-voting Module shall be disabled by CDSL upon expiry of aforesaid period.
- viii. The Scrutinizer, after scrutinizing the votes cast at the meeting through ballot first and thereafter through remote e-voting, will, not later than 48 hours of conclusion of the Meeting, make a consolidated scrutinizer's report and submit the same to the Chairman.

The results declared along with the consolidated scrutinizer's report shall be placed on the website of the Company. The results shall simultaneously be communicated to BSE Limited.

- ix. Subject to receipt of requisite number of votes, the Resolutions shall be deemed to be passed on the date of the Meeting, i.e. September 29, 2017.

**The instructions for shareholders voting electronically are as under:**

- (i) The voting period begins from **9.00 a.m. (IST) on September 26, 2017** and ends on **5.00 p.m. on September 28, 2017**. During this period shareholders' of the Company, holding shares either in physical form or in dematerialized form, as on the cut-off date i.e. **September 23, 2017**, may cast their vote electronically. The e-voting module shall be disabled by CDSL for voting thereafter.
- (ii) Shareholders who have already voted prior to the meeting date would not be entitled to vote at the meeting venue.
- (iii) The shareholders should log on to the e-voting website [www.evotingindia.com](http://www.evotingindia.com).
- (iv) Click on Shareholders/Members
- (v) Now Enter your User ID
- For CDSL: 16 digits beneficiary ID,
  - For NSDL: 8 Character DP ID followed by 8 Digits Client ID,
  - Members holding shares in Physical Form should enter Folio Number registered with the Company.
- (vi) Next enter the Image Verification as displayed and Click on Login.
- (vii) If you are holding shares in demat form and had logged on to [www.evotingindia.com](http://www.evotingindia.com) and voted on an earlier voting of any company, then your existing password is to be used.
- (viii) If you are a first time user follow the steps given below:

	<b>For Members holding shares in Demat Form and Physical Form</b>
PAN	Enter your 10 digit alpha-numeric *PAN issued by Income Tax Department (Applicable for both demat shareholders as well as physical shareholders) <ul style="list-style-type: none"> <li>Members who have not updated their PAN with the Company/Depository Participant are requested to use the first two letters of their name and the 8 digits of the sequence number in the PAN field.</li> <li>In case the sequence number is less than 8 digits enter the applicable number of 0's before the number after the first two characters of the name in CAPITAL letters. Eg. If your name is Ramesh Kumar with sequence number 1 then enter RA00000001 in the PAN field.</li> </ul>
Dividend Bank Details <b>OR</b> Date of Birth (DOB)	Enter the Dividend Bank Details or Date of Birth (in dd/mm/yyyy format) as recorded in your demat account or in the company records in order to login. <ul style="list-style-type: none"> <li>If both the details are not recorded with the depository or company please enter the member id / folio number in the Dividend Bank details field as mentioned in instruction (v).</li> </ul>

- ix. After entering these details appropriately, click on "SUBMIT" tab.
- x. Members holding shares in physical form will then directly reach the Company selection screen. However, members holding shares in demat form will now reach 'Password Creation' menu wherein they are required to mandatorily enter their login password in the new password field. Kindly note that this password is to be also used by the demat holders for voting for resolutions of any other company on which they are eligible to vote, provided that company opts for e-voting through CDSL platform. It is strongly recommended not to share your password with any other person and take utmost care to keep your password confidential.
- xi. For Members holding shares in physical form, the details can be used only for e-voting on the resolutions contained in this Notice.
- xii. Click on the EVSN of **Sangam Health Care Products Ltd.**
- xiii. On the voting page, you will see "**RESOLUTION DESCRIPTION**" and against the same the option "**YES/NO**" for voting. Select the option **YES** or **NO** as desired. The option YES implies that you assent to the Resolution and option NO implies that you dissent to the Resolution.
- xiv. Click on the "**RESOLUTIONS FILE LINK**" if you wish to view the entire Resolution details.
- xv. After selecting the resolution you have decided to vote on, click on "**SUBMIT**". A confirmation box will be displayed. If you wish to confirm your vote, click on "**OK**", else to change your vote, click on "**CANCEL**" and accordingly modify your vote.
- xvi. Once you "**CONFIRM**" your vote on the resolution, you will not be allowed to modify your vote.
- xvii. You can also take a print of the votes cast by clicking on "Click here to print" option on the Voting page.
- xviii. If a demat account holder has forgotten the login password then Enter the User ID and the image verification code and click on Forgot Password & enter the details as prompted by the system.
- (xix) **Shareholders can also cast their vote using CDSL's mobile app m-Voting available for android based mobiles. The m-Voting app can be downloaded from Google Play Store. Apple and Windows phone users can download the app from the App Store and the Windows Phone Store respectively. Please follow the instructions as prompted by the mobile app while voting on your mobile.**
- xx. **Note for Non – Individual Shareholders and Custodians**
  - ◆ Non-Individual shareholders (i.e. other than Individuals, HUF, NRI etc.) and Custodian are required to log on to [www.evotingindia.com](http://www.evotingindia.com) and register themselves as Corporates.
  - ◆ A scanned copy of the Registration Form bearing the stamp and sign of the entity should be emailed to [helpdesk.evoting@cdslindia.com](mailto:helpdesk.evoting@cdslindia.com).

- ◆ After receiving the login details a Compliance User should be created using the admin login and password. The Compliance User would be able to link the account(s) for which they wish to vote on.
  - ◆ The list of accounts linked in the login should be mailed to [helpdesk.evoting@cdslindia.com](mailto:helpdesk.evoting@cdslindia.com) and on approval of the accounts they would be able to cast their vote.
  - ◆ A scanned copy of the Board Resolution and Power of Attorney (POA) which they have issued in favour of the Custodian, if any, should be mailed to the scrutinizer's mail Id i.e. [suryapraksh@rna-cs.com](mailto:suryapraksh@rna-cs.com) to verify the same.
- xxi. In case you have any queries or issues regarding e-voting, you may refer the Frequently Asked Questions ("FAQs") and e-voting manual available at [www.evotingindia.com](http://www.evotingindia.com), under help section or write an email to [helpdesk.evoting@cdslindia.com](mailto:helpdesk.evoting@cdslindia.com).

By Order of the Board  
For Sangam Health Care Products Ltd,

Bala Gopal Addepalli  
Chairman  
DIN:01712903

Place: Secunderabad  
Date: September 05, 2017

**ANNEXURE TO THE NOTICE EXPLANATORY STATEMENT PURSUANT TO SECTION 102 OF THE COMPANIES ACT, 2013:**

**ITEM NOS. 3:**

The Companies Act, 2013 ('the Act') was notified effective April 1, 2014. Section 139 of the Act lays down the criteria for appointment and mandatory rotation of statutory auditors. Pursuant to Section 139 of the Act and the Rules made thereunder, it is mandatory to rotate the statutory auditors on completion of two terms of five consecutive years.

The Rules also lay down the transitional period that can be served by the existing auditors depending on the number of consecutive years for which an audit firm has been functioning as auditor in the same company. The incumbent auditors, M/s Jayant & Sadashiv, Chartered Accountants (Firm registration number : 001297S), have served the Company for over 10 years before the Act was notified and will be completing the maximum number of transitional period (three years) at the ensuing 23<sup>rd</sup> AGM.

The audit committee of the Company has proposed and on May 30, 2017, the Board has recommended the appointment of M/s K. R. Shekher, Chartered Accountants (Firm registration number 010828S) as the statutory auditors of the Company. M/s K. R. Shekher

will hold office for a period of five consecutive years from the conclusion of the 23<sup>rd</sup> Annual General Meeting of the Company till the conclusion of the 28<sup>th</sup> Annual General Meeting to be held in 2022.

Shareholders are requested to consider and if thought fit, to pass the following resolution as Ordinary resolution

**ITEM NOS. 4 TO 6**

Based on the recommendation of the Nomination & Remuneration Committee and Board of Directors in their respective meetings dated September 05, 2017, it is proposed to appoint the following as Independent director of the Company in the ensuing Annual General Meeting, for a period of five (5) years commencing from September 29, 2017

Sl No.	Name	DIN	Qualification
1.	Rajesh Kakker	0007931218	B.Tech(Computers)
2.	Ramu Chaganti	0007931223	B.S.C
3.	Madhavarao Mandalapu	0007931672	Metriculation

The Company has received a notice pursuant to Section 160 of the Companies Act, 2013 (the "Act") together with the requisite amount of deposit from Members signifying their intention to propose the appointment of the above stated candidates for the post of Independent Director in the Company.

The Company has also received a declaration from the above stated candidates confirming that they meet the criteria of independence as prescribed under the Act and Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"). They are also not disqualified from being appointed as a Director in terms of Section 164 of the Act and have given their consent to act as a Director of the Company. In the opinion of the Board, the proposed directors fulfil the conditions for their appointment as an Independent Director as specified in the Act and the Listing Regulations and they are independent of the management. Qualification of the proposed candidates are provided separately in the "Additional Information" section forming part of this notice.

The candidates are not related to any other Director and Key Managerial Personnel (KMP) of the Company and nor any directors, KMP and their relatives other than the proposed candidates and their relatives are, in any way, concerned or interested in the said resolutions.

The resolutions as set out in item nos. 4 to 6 of this Notice are accordingly commended for your approval.

**ADDITIONAL INFORMATION OF DIRECTORS BEING RE-APPOINTED**

(Pursuant Reg 36(3) to SEBI (LODR) Regulations, 2015)


Name	Mr Bala Gopal Addepalli
Date of Birth	August 25, 1967
Date of Appointment	February 02, 2015
Qualification	Commerce Graduate.
Directorship held in other Companies	Nil
Membership/Chairmanships of Committees across public Companies	Nil.
Brief Profile covering experience, achievements etc.	He is about 42 years and has a unit of manufacturing of I V Sets in the name of M/S Sai Healthcare at Jeedimetala, Hyderabad. He is supplying I V Sets to Govt. of Andhra Pradaesh since 7 years. He is also in infrastructure business and presently constructing IIIT building at BASARA, Telangana
Shares held in the Company	30,01,000 Equity Shares of Rs.10/- each

Name	Rajesh Kakkera
Date of Birth	March 24, 1987
Date of Appointment	-
Qualification	B.Tech(Computers)
Directorship held in other Companies	NIL
Membership/Chairmanships of Committees across public Companies	NIL
Brief Profile covering experience, achievements etc.	He is Computer engineer and having experience for 6 years
Shares held in the Company	NIL

Name	Madhavarao Mandalapu
Date of Birth	March 10, 1982
Date of Appointment	-
Qualification	Metriculation
Directorship held in other Companies	NIL
Membership/Chairmanships of Committees across public Companies	NIL
Brief Profile covering experience, achievements etc.	He is a business person and having 15 years experience
Shares held in the Company	NIL

Name	Ramu Chaganti
Date of Birth	August 17, 1983
Date of Appointment	-
Qualification	B.S.C
Directorship held in other Companies	NIL
Membership/Chairmanships of Committees across public Companies	NIL
Brief Profile covering experience, achievements etc.	He is working and having experience more than 10 years
Shares held in the Company	NIL

IN TERMS OF THE REQUIREMENTS OF THE SECRETARIAL STANDARD ON GENERAL MEETINGS (SS-2) ISSUED BY THE INSTITUTE OF THE COMPANY SECRETARIES OF INDIA, ROUTE MAP FOR THE LOCATION OF THE VENUE OF THE 23<sup>rd</sup> ANNUAL GENERAL MEETING IS GIVEN BELOW:





## DIRECTORS' REPORT

Dear Shareholders,  
**SANGAM HEALTH CARE PRODUCTS LIMITED,**

We have pleasure in presenting the 23rd Annual Report on the business and operations of Company and Financial Results for the year ended 31st March, 2017.

### FINANCIAL RESULTS

As per the requirements Section 134 of the Companies Act, 2013 and Rule 8(5) (i) of Companies (Accounts) Rules, 2014, the summarized Financial Results of the Company are given hereunder:

(₹. in lakhs)

Particulars	2016-2017	2015-16
Total Income	2373.69	2343.85
Total Expenditure before Finance cost & Depreciation	2400.66	1676.95
Finance cost	504.86	379.99
Depreciation	152.16	152.56
Profit/(Loss) before Taxation	(683.99)	(153.86)
Provision for tax	1.66	-
Profit/(Loss) after Taxation	(685.66)	(153.86)

### OPERATIONS AND BUSINESS OUTLOOK:

During the year under review, the Company recorded a total income of Rs. 2373.69 lakhs and a net Loss of Rs. 685.66 lakhs against income of Rs. 2343.85 lakhs and a net loss of Rs. 153.86 lakhs in the previous year. Company is adopting a very cautious approach towards its business in view of the risk involved in this business to increase the level of profit.

### REVOCATION OF SUSPENSION OF COMPANY'S SCRIP

Revocation of suspension of the Company's Shares in BSE Limited is in progress.

### EVENTS SUBSEQUENT TO THE DATE OF FINANCIAL STATEMENTS:

As per the requirements Section 134 (3) (l) of the Companies Act, 2013, we want to declare that, there are no significant material changes and commitments affecting financial position of the company between 31st March, 2017 and the date of Board's Report.

**CHANGE IN THE NATURE OF BUSINESS:**

As per the requirements Rule 8 (5) (ii) of Companies (Accounts) Rules, 2014, we want to declare that, there is no significant change in the nature of business of the company during the last financial year.

**SHARE CAPITAL AND CLASSIFICATION OF COMPANY:**

The authorized capital of the Company as on 31<sup>st</sup> March, 2017 was Rs. 150,000,000/- divided into 15,000,000 equity shares of Rs. 10/- each.

The Subscribed, Issued and Paid-up capital of the Company as on 31<sup>st</sup> March, 2017 was Rs. 148,607,000/- divided into 14,860,700 equity shares of Rs. 10/- each.

**DIVIDEND**

Your directors express their inability to recommend any dividend for the financial year 2016-2017.

**FIXED DEPOSITS:**

Your Company has not accepted/invited any deposits from the public for the year under review as per Section 73 of the Companies Act, 2013 and the rules made there under.

**DIRECTORS AND KEY MANAGERIAL PERSONNEL**

As per the requirements Rule 5 (iii) of Companies (Accounts) Rules, 2014, we want to inform you that, the following are the Directors and Key Managerial Personnel of the Company as on the date of the Report.

SI No.	Name	Designation	DIN
1.	Mr. Bala Gopal Addepalli	Managing Director	01712903
2.	Mr. Khushwant Singh	Independent Director	00500962
3.	Mr. Basawaraj Nagabusappa Sajjan	Director	05209651
4.	Mrs. Padma Ghanakota	Director	07078176
5.	Mr. Lingaraj Shantalingappa Patil*	Director	00731663

**A. RETIREMENT BY ROTATION**

Pursuant to provisions of the Companies Act, 2013, Mr. Bala Gopal Addepalli (DIN: 01712903, Director will retire at the ensuing Annual General Meeting and being eligible, offers himself for reappointment. The Board recommends his re-appointment.

**B. APPOINTMENT**

During the year under review, no directors were appointed as the director of the Company. However, Board in its meeting dated September 05, 2017 has recommended to appoint the

following candidate as Independent director in the ensuing Annual General Meeting for a period of five (5) years commencing from September 29, 2017.

SI No.	Name	DIN
1.	Rajesh Kakker	0007931218
2.	Ramu Chaganti	0007931223
3.	Madhavarao Mandalapu	0007931672

### C. CESSATION

During the year under review, Mrs. Ramana Ganakota (DIN: 07067685) & Mr. Venkata Subramanya Sharma Devarkonda (DIN: 07067129) resigned from the directorship of the Company w.e.f. February 17, 2017 and Mr. Pradyut Waghay (DIN: 00765063) tendered his resignation w.e.f. September 02, 2017 and the same has been noted and taken on record by the Board in its meeting dated September 05, 2017.

\*Mr. Lingaraj Shantalingappa Patil (DIN: 00731663) has tendered his resignation on February 28, 2015 and the same has not been accepted by the management.

### D. EVALUATION OF THE BOARD'S PERFORMANCE

As per provisions of the Companies Act, 2013 and Regulation 17(10) of the SEBI (LODR) Regulations, 2015, The Company has devised a policy for performance evaluation of Independent Directors, Board, Committees and other individual directors which include criteria for performance evaluation of executive and non-executive director.

The Directors were overall satisfied with the evaluation results, which reflected the overall engagement of the Board and its Committees with the Company.

### E. MANAGEMENT DISCUSSION AND ANALYSIS REPORT

Management's Discussion and Analysis Report for the year under review, in terms of the provisions of Regulation 34 of the SEBI (LODR) Regulations, 2015, presented in a separate section forming part of the Annual Report. **(Annexure I).**

### F. REMUNERATION POLICY

The Board has, on the recommendation of the Nomination & Remuneration Committee framed a policy for selection and appointment of Directors, Senior Management and their remuneration. The Remuneration Policy is attached to this report as **Annexure II.**

**G. DECLARATION BY INDEPENDENT DIRECTORS**

In accordance with Section 149(7) of the Companies Act, 2013, each Independent Director has confirmed to the Company that they meet the criteria of independence as laid down in Section 149(6) of the Companies Act, 2013 and Regulation 16(1)(b) of the SEBI (LODR) Regulations, 2015..

The Company's Independent Directors meet on May 05, 2017, without the presence of Executive Directors or KMP. Matters pertaining to the Company's affairs was put forth their views to the chairman of the Independent Director Committee Meeting. Pursuant to the provisions of the Companies Act, 2013 and the SEBI (LODR), Regulations, 2015 to discuss:

- ▶ Evaluation of the performance of the Chairman of the Company, taking into account the views of the Executive and Non-Executive Directors.
- ▶ Evaluation of the performance of Non Independent Directors and the Board of Directors as a Whole;
- ▶ Evaluation of the quality, content and timelines of flow of information between the management and the Board that is necessary for the Board to effectively and reasonably perform its duties.

**H. DIRECTORS' RESPONSIBILITY STATEMENT:**

To the best of their knowledge and belief and according to the information and explanations obtained by them, your Directors make the following statements in terms of Section 134(3)(c) of the Companies Act, 2013:

- (a) **THAT** in the preparation of the annual accounts, the applicable accounting standards had been followed along with proper explanation relating to material departures;
- (b) **THAT** the directors had selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the company at the end of the financial year and of the profit and loss of the company for that period;
- (c) **THAT** the directors had taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of this Act for safeguarding the assets of the company and for preventing and detecting fraud and other irregularities;
- (d) **THAT** the directors had prepared the annual accounts on a going concern basis;
- (e) **THAT** the directors had laid down internal financial controls to be followed by the company and that such internal financial controls are adequate and were operating effectively; and
- (f) **THAT** the directors had devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

**I. VIGIL MECHANISM/WHISTLE BLOWER POLICY:**

The Board of Directors of the Company have adopted Whistle Blower Policy. This policy is formulated to provide an opportunity to employees to raise concerns and to access the Audit Committee in good faith, in case they observe unethical and improper practices or any other

wrongful conduct in the Company, to provide necessary safeguards for protection of employees from reprisals or victimization and to prohibit managerial personnel from taking any adverse personnel action against those employees.

There were no complaints received during the year 2016-17.

**J. PREVENTION OF INSIDER TRADING:**

In terms of the provisions of SEBI (Prohibition of Insider Trading) Regulation 2015, effective from 15.05.2015, the Board of Directors of the Company has adopted the Code of Practices and Procedure and Code of Conduct for fair disclosure of unpublished price sensitive information. The object of this code is to protect the interest of the shareholders at large, to prevent misuse of any price sensitive information and to prevent any insider trading activity by dealing in shares of the company by the Directors, designated employees and other employees of the Company.

The Board is responsible for implementation of the Code.

Formulated the Code of Conduct to Regulate, Monitor and Report Trading by Insiders in terms of Regulation 9 of SEBI (Prohibition of Insider Trading) Regulations, 2015. Mr. G S R Murthy has been designated as Compliance Officer for the purpose of this Code. All Board Directors and the designated and other employees have confirmed compliance with the Code

**K. FAMILIARIZATION PROGRAM:**

The details of programme for familiarization of Independent Directors with the Company, nature of the industry in which the Company operates and related matters are made aware to the independent Director. Further at the time of appointment they were issued a formal letter of appointment, outlining their duty, responsibilities, role and functions.

**AUDITORS & AUDITORS' REPORT**

**A. STATUTORY AUDITORS:**

As per second proviso to Section 139(2) of the Companies Act, 2013, (the Act), a transition period of three years from the commencement of the Act is provided to appoint a new auditor if the existing auditor's firm has completed two terms of five consecutive years. accordingly, M/s K. R. Shekher, Chartered Accountants, Secunderabad are proposed to be appointed as auditors for a period of five years commencing from the conclusion of 23<sup>rd</sup> AGM till the conclusion of the 28<sup>th</sup> AGM. They have confirmed that their appointment, if made, would be within the limits specified under Section 141(3)(g) of the Act.

They have further confirmed that they are not disqualified to be appointed as statutory auditors in terms of the provisions of the proviso to Section 139(1), Section 141(2) and Section 141(3) of the Act and the provisions of the Companies (Audit and Auditors) Rules, 2014. The Audit Committee and the Board of Directors recommend the appointment of M/s K. R. Shekher, Chartered

Accountants, Secunderabad, as statutory auditors of the Company from the conclusion of the 23rd AGM till the conclusion of 28<sup>th</sup> AGM, to the shareholders.

The Statutory Auditors' Report obtained from M/s Jayant and Sadashiv does not contain any reservation, qualification or adverse remark. Auditors have not reported any offense involving fraud committed against the Company by the officers or employees of the Company under sub section (12) of section 143 to Board.

The Statutory Audit Report for the financial year 2016-17 is annexed herewith as **Annexure III** to this Report.

## **B. SECRETARIAL AUDITOR**

During the year, The Company has appointed R & A Associates, Company Secretaries, Hyderabad as Secretarial Auditor. The Secretarial Audit Report (SAR) for the financial year 2016-17 is annexed herewith as **Annexure IV** to this Report. The Secretarial Audit Report contains following qualification and reply by management.

<b>Secretaries auditor observation</b>	<b>Reply by management</b>
Non appointment of Independent director and Company Secretary.	Management is in the process of identifying appropriate candidates to be appointed as Independent Director and Company Secretary
Connectivity with Central Depository Services Limited (CDSL) only	As on March 31, 2017 Companies shareholders are 650 and trading of share were suspended on 10th September, 2001, due to this company not obtained connectivity with NSDL
Delay in submission of information/disclosures to BSE Limited.	Management commits that hence forth information will furnished to stock exchange promptly
Demat of shares held by promoters	Promoters are in the process of demat of shares
Non payment of Listing fees	Company being a sick company has financial crunch; however, company will make the payment.

### **C. COST AUDITOR**

During the year under review, the Company was not required to maintain cost records and get them audited by Cost Auditor.

### **TRANSFER TO RESERVE**

The Company has not transferred any amount to reserve in the financial year.

### **INDUSTRIAL RELATION**

The Management and Labour relations were very cordial and harmonious and continued to remain cordial at all the level during the year under review.

### **CORPORATE GOVERNANCE**

A separate report on Corporate Governance is enclosed as a part of this Annual Report. A certificate from the Auditors of the Company regarding compliance with Corporate Governance is annexed to the Report on Corporate Governance.

The Company has complied with the requirements about code of conduct for Board members and Senior Management Personnel. The said policy is available on the website of the Company.

Pursuant to Schedule V of SEBI (LODR) Regulations, 2015 the declaration signed by the Managing Director affirming compliance of the Code of Conduct by the Directors and Senior Management personnel of the Company for the financial year 2016-2017 is annexed and forms part of the Corporate Governance Report Annexure V.

### **CORPORATE SOCIAL RESPONSIBILITY**

The Company was not required to constitute a CSR Committee as the Company has not met any of the thresholds mentioned in Section 135 of the Companies Act, 2013 during the financial year under review. Hence reporting about policy on Corporate Social Responsibility and the initiatives taken are not applicable to the Company.

### **PARTICULARS OF EMPLOYEES AND RELATED DISCLOSURES**

The information required pursuant to Section 197(12) of Companies Act, 2013 read with Rule 5(1) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 in respect of the employees of the Company, will be provided upon request. In terms of Section 136 of the Act, the Report and Accounts are being sent to the members and others entitled thereto, excluding the information on employees' particulars which is available for inspection by the members at the Registered Office of the Company during business hours on working days of the Company up to the date of the ensuing Annual General Meeting. If any member is interested in obtaining a copy thereof, such member may write to Company in this regard.

No employee was in receipt of remuneration in excess of limits prescribed under Rule 5(2) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 and

hence the disclosure as required under Rules 5(2) and 5(3) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 is not required.

## RELATED PARTY TRANSACTIONS

All related party transactions that were entered into during the financial year were on arm's length basis and were in the ordinary course of business. There are no materially significant related party transactions made by the Company with Promoters, Directors, Key Managerial Personnel or other designated persons which may have a potential conflict with the interest of the Company at large. Annexure VI

The Policy on materiality of related party transactions as approved by the Board.

Your Directors draw attention of the members to Notes No. 24 to the financial statement, 2016-17, which sets out related party disclosures.

## PARTICULARS OF LOANS, GUARANTEES OR INVESTMENTS

The Company has not made any loan, given guarantee, provided security or made investments pursuant to the provisions of Section 186 of Companies Act, 2013.

## DISCLOSURES

### A. EXTRACT OF ANNUAL RETURN

Extract of Annual Return of the Company is annexed herewith in the form of MGT-9 as Annexure VII to this Report.

### B. COMPOSITION OF SUB COMMITTEE:

#### NAME OF THE COMMITTEE AND MEMBERS OF COMMITTEE

##### a) AUDIT COMMITTEE

- |   |                                   |                      |
|---|-----------------------------------|----------------------|
| 1 | Mr. Khushwant Singh - Chairman    | Independent Director |
| 2 | Mr. Pradyut Waghray - Member      | Independent Director |
| 3 | Mr. Bala Gopal Addepalli - Member | Executive Director   |

##### b) NOMINATION AND REMUNERATION COMMITTEE

- |   |                                |                        |
|---|--------------------------------|------------------------|
| 1 | Mr. Khushwant Singh - Chairman | Independent Director   |
| 2 | Mr. Pradyut Waghray - Member   | Independent Director   |
| 3 | Mrs. Padma Ghanakota – Member  | Non Executive Director |

*Note: Mrs. Padma Ghanakota was appointed as a member of Nomination & Remuneration Committee in the Board Meeting dated February 13, 2017; in place of Mr. Basawaraj Nagabusappa Sajjan who showed his inability to continue as the member of the Committee*

##### c) STAKEHOLDERS RELATIONSHIP COMMITTEE



1	Mr. Khushwant Singh – Chairman	Independent Director
2	Mr. Pradyut Waghray – Member	Independent Director
3	Mr. Bala Gopal Addepalli - Member	Executive Director

*Note: Mr. Khushwant Singh and Mr. Pradyut Waghray were appointed as a members in Stakeholders relationship committee in the Board Meeting dated February 13, 2017 ; in place of Mr. Basawaraj Nagabusappa Sajjan who showed his inability to continue as the member of the Committee*

#### **C. NUMBER OF BOARD MEETINGS:**

As per the requirements Section 134 (3) (b) of the Companies Act, 2013, we want to inform you that, the Board of Directors met 6 times during this financial year. For further details, please refer report on Corporate Governance. The Maximum interval between 2 meetings did not exceed 120 days, as prescribed under Companies Act, 2013.

#### **D. LISTING**

The equity share of the Company is listed with Bombay Stock Exchange (BSE). The Security ID of the company is **SANHP** and the Security Code is **531625**.

\* Listing fees is payable to BSE Ltd. including financial year 2016-17.

\* Share Trading is suspended.

#### **RISK MANAGEMENT**

The Board of your company has formulated a risk management policy in connection with the risk that the organization faces in its day to day business such as strategic, financial, credit, market, liquidity, security, property, IT, legal, regulatory etc. The board reviews the policy in regular interval.

#### **CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION, FOREIGN EXCHANGE EARNINGS AND OUTGO**

The particulars regarding Research & Development Conservation of energy, technology absorption in terms of Section 217(1)(e) of the Companies Act, 1956 read with Companies (Disclosure of Particulars in the Report of Board of Directors) Rules, 1988 are given in the "Annexure VIII" forming part of this Report.

#### **GENERAL**

Your Directors state that no disclosure or reporting is required in respect of the following items as there were no transactions on these items during the year under review:

- a. The Company has no subsidiaries, joint ventures or associate companies.
- b. No significant or material orders were passed by the Regulators or Courts or Tribunals which impact the going concern status and Company's operations in future.

- c. The Company has in place adequate internal financial controls with reference to financial statements. These controls ensure the accuracy and completeness of the accounting records and preparation of reliable financial statements.

#### **POLICY ON SEXUAL HARASSMENT**

The Company has adopted policy on Prevention of Sexual Harassment of Employees at workplace in accordance with The Sexual harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013.

During the year under review, the Company has not received any complaints pertaining to sexual harassment.

#### **CAUTIONARY STATEMENT**

The statements contained in the Board's Report and Management Discussion and Analysis contain certain statements relating to the future and therefore are forward looking within the meaning of applicable securities, laws and regulations. Various factors such as economic conditions, changes in government regulations, tax regime, other statutes, market forces and other associated and incidental factors may however lead to variation in actual results.

#### **SECRETARIAL STANDARDS**

Your company has complied with the requirements of the Secretarial Standards, issued by Institute of Company Secretaries of India and which is approved by the Central Government

#### **ACKNOWLEDGEMENTS**

The Directors thank the Company's Bankers and officials of concerned Government Departments for their co-operation and continued support to the Company.

The Board would also like to thank the Company's shareholders, customers, suppliers for the support and the confidence which they have reposed in the management.

Your Directors wish to place on record their appreciation to employees at all levels for their hard work, dedication and commitment. The Board also desires to place on record its sincere

By Order of the Board  
**For Sangam Health Care Products Limited**

Place : Secunderabad  
Date : September, 05, 2017

**(BALAGOPAL ADDEPALLI)**  
**Managing Director**  
**DIN: 01712903**

**MANAGEMENT DISCUSSION ANALYSIS****1) ECONOMY – REVIEW AND OUT LOOK**

The year gone by was a challenging one for the Indian Pharmaceutical Industry as it faced couple of challenges during the year impacting its growth. National Pharmaceutical Pricing Authority (NPPA) announced reduction in the prices of more drugs in the beginning of the financial year, affecting the pricing of such drugs adversely. As a result of this, portfolio of products under the National List of Essential Medicines (NLEM) de-grew in value terms though it registered volume growth during the year.

Apart from the above factor Central Government's decision to demonetize Rs. 500 and Rs. 1000 currency notes announced on November 08,2016 also had an impact on the Indian Pharmaceutical Industry.

**2) OPPORTUNITIES & THREATS**

The pharmaceutical industry is highly competitive and the challenges are from both the Indian manufacturers who have similar production facilities as well as those abroad. Human resources with similar skills, talents and experiences in the industry are mobile between competing companies. Price pressures from foreign players are expected to stay. Going forward, there is a risk of inability to maintain current margins on its products. Price sensitivities get tested in a crowded market where price tends to sag while volume business gets done. Competing pharmaceutical companies have several similar bio-equivalent products in the same market manufactured at facilities that have been approved by the highest regulatory authorities. All of them stay focused on the same markets resulting in price elasticity being tested and margins eroding.

**3) CERTIFICATION & QUALITY**

The company is accredited with ISO 9001:2008 certification for Manufacturing and supply of Medical Devices including sterile infusion sets (IV sets), sterile transfusion sets (B.T.Sets), Sterile Hypodermic Needles, Sterile Syringes and Urine Bags.

**4) SEGMENT WISE / PRODUCT WISE PERFORMANCE**

The Company manufactures IV sets, Disposable Syringes and Disposable Needles. The Annual Capacity of IV Sets is 40 Millions, Disposable Syringes is 264 Millions and Disposable Needles is 135 Millions per Annum. As the Company has completed the de-bottlenecking of the IV Set, Capacity is increased to 40 Millions from July 07 onwards.

5) **OUTLOOK**

***“Healthcare should be extended to the people at an affordable cost and the industry needs to set its priorities straight by treating healthcare activity as a service activity rather than a business activity”.***

Our Company has emerged as one of the leaders in the Medical Disposables market and it's continuous efforts for a strong presence in the domestic market. There has been growing awareness among the end users about the threats posed while using Low Quality Infusion sets produced and marketed by the Unorganized Sector. There were conscious efforts from the government which helped the cause more. The share of unorganized sector is falling drastically and there was a corresponding spurt in the demand for quality products in addition to the normal increase in demand.

The Company is making all efforts to meet the increase in demand for our products.

6) **RISKS**

There is no visible silver lining in the job market yet. With government extending price controls over the medical devices and proposing generic prescriptions, healthcare industry foresee millions of employees losing jobs in the next two years.

7) **INTERNAL CONTROL SYSTEMS**

The Company has sound and adequate internal control systems commensurate with its size and nature of business. We constantly upgrade our systems for incremental improvements, because we firmly believe that 'change is the only permanent thing'. The Audit Committee of the Board periodically reviews these systems. These systems ensure protection of assets and proper recording of transactions and timely reporting. Internal audit is being carried out by an independent firm of chartered accountants on a quarterly basis. The Audit Committee also regularly reviews the periodic reports of the Internal Auditors. Issues raised by Internal Auditors and Statutory Auditors are discussed and addressed by the Audit Committee. Audit Committee constantly tries to add value by evaluating existing systems.

**8) FINANCIAL PERFORMANCE**

<b>Turnover</b>	<b>Sharecapital</b>
The Gross Sales of the Company is Rs. 2373.69 Lakhs in FY 16-17 and Rs. 2343.85 Lakhs in F.Y. 2015-16	The Company has not allotted any shares during the year under review and the paid up share capital as on March 31, 2017 is Rs. 1486.07 lakhs divided in to 148.60 Lakhs Equity Shares of Rs. 10/- each.
<b>Reserves &amp; Surplus</b>	<b>Net worth</b>
The Reserves and Surplus of the Company has down from a negative balance of Rs. 3335.34 Lakhs in F.Y. 2015-16 to Rs. 4021.01 Lakhs in previous FY-2016-17	The net worth of the Company has deceased from a negative figure of Rs. 2619.29 lakhs to a negative figure of 3304.95 lakhs
<b>Secured/unsecured loans</b>	<b>Fixed assets</b>
There was increase of loans as the present F.Y. 2016-17 is Rs. 3962.15 Lakhs as compared to previous F.Y. 2015-16 is Rs. 3608.69	The Company's Fixed Assets are at the present F.Y. 2016-17 is 2144.11 lakhs as compared to previous F.Y. 2015-16 is Rs. 2262.58 lakhs
<b>Tax</b>	<b>Net loss</b>
The Company has provided for a sum of Rs. 1.66 Lac as current year tax.	The Company's Net Loss after Tax and extraordinary expenses during the FY 2016-17 was Rs. 685.66 Lacs as compared to Rs. 153.86 lakhs in FY 2015-16
<b>Dividend</b>	<b>EPS</b>
Board has not recommdated any dividend for the financial year under review due to unavailability of profits.	Earning per share has been in negative and has fallen further from the last year I.e. from (1.04) to (4.61)

**9) HUMAN RESOURCES**

Sangam is a professionally managed company with highly competent and committed industry professionals forming a tight-knit team of dedicated colleagues. The corporate promises to focus on performing and delivering on patient-safety. The knowledge, expertise and skills of the team form a strong foundation of the Company's progress, and hence considerable strategic emphasis is laid at people development and leadership. The overall target is to enhance business growth by enabling engagement and performance. This is achieved by having the right people supported by leadership of able management working together towards organizational goals.

appreciation for the support and co-operation that the company received from the customers, auditors, consultants and all others associated with the company.

The company always looked upon them as partners in its progress and has happily shared the rewards of growth. It will be the company's endeavor to build and nurture strong links with trade based on mutuality, respect and co-operation.

## ANNEXURE - II

### REMUNERATION POLICY

#### 1. INTRODUCTION

Sangam Healthcare Products Ltd recognizes the importance of aligning the business objectives with specific and measurable individual objectives and targets. The Company has therefore formulated the remuneration policy for its Directors, Key Managerial Personnel and other employees keeping in view the following objectives:

- ◆ Ensuring that the level and composition of remuneration is reasonable and sufficient to attract, retain and motivate, to run the company successfully.
- ◆ Ensuring that relationship of remuneration to performance is clear and meets the performance benchmarks.
- ◆ Ensuring that remuneration involves a balance between fixed and incentive pay reflecting short and long term performance objectives appropriate to the working of the company and its goals.

#### 2. SCOPE AND EXCLUSION:

This Policy sets out the guiding principles for the Nomination and Remuneration Committee for recommending to the Board the remuneration of the directors, key managerial personnel and other employees of the Company.

#### 3. TERMS AND REFERENCES:

In this Policy, the following terms shall have the following meanings:

**"Director"** means a director appointed to the Board of the Company.

**"Key Managerial Personnel"** means :

- (i) the Chief Executive Officer or the Managing Director or the manager;
- (ii) the Company secretary;
- (iii) the Whole-time director;
- (iv) the Chief Financial Officer; and
- (v) such other officer as may be prescribed under the Companies Act, 2013

**"Nomination and Remuneration Committee"** means the committee constituted by Sangam Board in accordance with the provisions of Section 178 of the Companies Act, 2013 and Clause 49 of the Equity Listing Agreement.

#### 4. POLICY:

##### A. Criteria for Appointment of Non-Executive Directors & Independent Directors

- a) The Non-Executive Directors shall be of high integrity with relevant expertise and experience so as to have a diverse Board with Directors having expertise in the fields of marketing, finance, taxation, law, governance and general management.
- b) In case of appointment of Independent Directors, the Nomination & Remuneration (N&R) Committee shall satisfy itself with regard to the independent nature of the Directors vis-à-vis the Company so as to enable the Board to discharge its function and duties effectively.
- c) The N&R committee shall ensure that the candidate identified for appointment as a director is not disqualified for appointment under section 164 of the Companies Act 2013.
- d) In case of re-appointment of Non-Executive Directors & Independent Directors, the Board shall take into consideration the performance evaluation of the Director and his engagement level.

#### **Remuneration of Non-Executive Directors & Independent Directors**

- i. A Non-Executive Director & Independent Director shall be entitled to receive sitting fees for each meeting of the Board or Committee of the Board attended by him, of such sum as may be approved by the Board of Directors within the overall limits prescribed under the Companies Act 2013 and the Companies (Appointment and Remuneration of Managerial Personnel) Rules 2014 including any amendment or modification thereto as may be in force;
- ii. The Independent Directors of the Company shall not be entitled to participate in the Stock Option Scheme of the Company, if any, introduced by the Company.

#### **B. Criteria for Appointment of Executive Directors and Key Managerial Personnel (KMP)**

For the purpose of appointment of any Executive Director and Key Managerial Personnel (KMP), the N&R Committee shall identify persons of integrity who possess relevant expertise, experience and leadership qualities required for the position. The Committee shall also ensure that the incumbent fulfils such other criteria as laid down under the Companies Act, 2013 read with Rules made there under or other applicable laws.

#### **Remuneration of Executive Directors & KMP**

- i. The Board, on the recommendation of the Nomination and Remuneration (N&R) Committee, shall review and approve the remuneration payable to the Executive Directors of the Company within the overall limits prescribed under Companies Act, 2013 including any statutory modification or amendment thereto as may be in force, subject to approval by the shareholders in General Meeting.
- ii. The Board, on the recommendation of the N&R Committee, shall also review and approve the remuneration payable to the Key Managerial Personnel of the Company.
- iii. The remuneration of the Executive Directors and KMP may be broadly divided into fixed and variable components. The fixed component comprises salary, allowances, perquisites, amenities and retiral benefits. The variable component comprises performance bonus.

#### **C. Remuneration to Other Employees:**

**INDEPENDENT AUDITORS' REPORT****To the Members of Sangam Health Care Products Limited  
Report on the Financial Statements**

We have audited the accompanying financial statements of **Sangam Health Care Products Limited ("the Company")**, which comprise the Balance Sheet as at 31<sup>st</sup> March, 2017, the Statement of Profit and Loss and the Cash Flow Statement for the year then ended, and a summary of significant accounting policies and other explanatory information.

**Management's Responsibility for the Financial Statements**

The Company's Board of Directors is responsible for the preparation of these financial statements in terms of the requirements of the Companies Act 2013 (hereinafter referred to as 'the act') that give a true and fair view of the financial position, financial performance, cash flows and changes in equity of the Company in accordance with the accounting principles generally accepted in India, including the Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder. The respective Board of Directors of the company are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; the selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error which have been for the purpose of preparation of the financial statements by the Directors of the Company, as aforesaid.

**Auditors' Responsibility**

Our responsibility is to express an opinion on these financial statements based on our audit. While conducting the audit, we have taken into account the provisions of the Act, the accounting and auditing standards and matters which are required to be included in the audit report under the provisions of the Act and the Rules made thereunder.

We conducted our audit in accordance with the Standards on Auditing specified under Section 143(10) of the Act. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.



An audit involves performing procedures to obtain audit evidence about the amounts and the disclosures in the financial statements. The procedures selected depend on the auditors' judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal financial control relevant to the Company's preparation of the financial statements that give a true and fair view in order to design audit procedures that are appropriate in the circumstances. An audit also includes evaluating the appropriateness of the accounting policies used and the reasonableness of the accounting estimates made by the Company's Board of Directors, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence obtained is sufficient and appropriate to provide a basis for our audit opinion on the financial statements.

### **Opinion**

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, including the financial position of the Company as at 31 March, 2017 and its loss and Cash Flows and the changes in equity for the year then ended on that date.

### **Emphasis of Matter**

We draw your attention to Note 4.2 of the additional information to the financial statements which describe the uncertainty related to outcome of the notice received under section 13(2) of Securitisation and Reconstruction of Financial Assets and Enforcement of Security Interest Act, 2002 vide their notice No.NPA/SHCPL dated: 15 March 2017 for recovery of outstanding dues of Rs.33.06 crores and future interest at agreed contractual rate. Our opinion is not modified with respect to this matter.

### **Report on Other Legal and Regulatory Requirements**

1. As required by the Companies (Auditor's Report) Order, 2016 ("the Order"), issued by the Central Government of India in terms of sub-section (11) of section 143 of the Act, we give in the "**Annexure A**", a statement on the matters specified in the paragraph 3 and 4 of the Order.

2. As required by section 143(3) of the Act, we report, that:

a. we have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purpose of our audit of the aforesaid financial statements.

- b. in our opinion, proper books of account as required by law relating to preparation of the aforesaid financial statements have been kept by the Company so far as it appears from our examination of those books.
- c. the Balance Sheet, the Statement of Profit and Loss and Statement of the Cash Flow and changes in equity dealt with by this Report are in agreement with the relevant books of account maintained for the purpose of preparation of the financial statements.
- d. in our opinion, the aforesaid financial statements comply with the Accounting Standards specified under section 133 of the Act, read with relevant rule issued thereunder.
- e. On the basis of written representations received from the directors as on March 31, 2017 taken on record by the Board of Directors, none of the directors is disqualified as on March 31, 2017 from being appointed as a director in terms of Section 164 (2) of the Act;
- f. With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate Report in "**Annexure B**"; and
- g. With respect to the other matters to be included in the Auditors' Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us;
- i. The company does not have any pending litigations which would impact its financial position.
  - ii. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.
  - iii. There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company.
  - iv. The company has provided requisite disclosures in its Financial Statements as to holding as well as to dealings in Specified Bank Notes during the period 8th November, 2016 to 30th December, 2016 and these are in accordance with the books of accounts maintained by the Company. Refer Note 25 to the Financial Statements.

For Jayant & Sadashiv  
Chartered Accountants

Firm's Registration Number: 001297S

**Jayant Palnitkar**  
Partner  
Membership No. 020851

Place: Hyderabad  
Date: 30<sup>th</sup> May, 2017

## “Annexure A” to the Independent Auditors’ Report

The Annexure referred to in Independent Auditors’ Report to the members of the Company on the financial statements for the year ended 31<sup>st</sup> March, 2017, we report that:

- 1) (a) The Company has maintained proper records showing full particulars, including quantitative details and situation of fixed assets;
- (b) The Company has a regular programme of the physical verification of its fixed assets by which fixed assets are verified in a phased manner over a period of three year. In accordance with this program, certain fixed assets were verified during the year and no material discrepancies were noticed on such verification. In our opinion, this periodicity of physical verification is reasonable having regard to the size of the Company and the nature of its assets.
- (c) The title deed of immovable properties, as disclosed in Schedule 10 to the financial statements, are held in the name of the company as at the balance sheet date.

Particulars	Land	Factory Buildings
Gross Block as on 31 <sup>st</sup> March, 2017	7,90,50,000	6,51,30,130
Net Block as on 31 <sup>st</sup> March, 2017	7,90,50,000	4,23,36,184

- 2) (a) The management has conducted the physical verification of inventory at reasonable intervals.
  - (b) The discrepancies noticed on physical verification of the inventory as compared to books records which has been properly dealt with in the books of account were not material.
- 3) In our opinion and according to the information and explanations given to us, the Company has not granted any loans, secured or unsecured to companies, firms, limited liability partnerships or other parties covered in the register maintained under section 189 of the Act. Accordingly, the provisions of clause 3 (iii) (a) to (c) of the Order are not applicable to the Company and hence not commented upon.
- 4) In our opinion and according to the information and explanations given to us, the company has complied with the provisions of section 185 and 186 of the Companies Act, 2013 in respect of loans, investments, guarantees, and security.
- 5) The Company has not accepted any deposits from the public and hence the directives issued by the Reserve Bank of India and the provisions of Sections 73 to 76 or any other relevant provisions of the Act and the Companies (Acceptance of Deposit) Rules, 2015 with regard to the deposits accepted from the public are not applicable.
- 6) As informed to us, the maintenance of Cost Records has not been specified by the Central Government under sub-section (1) of Section 148 of the Act, in respect of the activities carried on by the company.

- 7) (a) According to information and explanations given to us and on the basis of our examination of the books of account and records.
- i. The Company has been generally regular in depositing the following undisputed statutory dues: Duty of Excise, Value Added Tax, Cess with the appropriate authorities.
  - ii. There has been irregularity in depositing the following undisputed statutory dues: Service tax, Employee State Insurance and Provident Fund with the appropriate authorities.
  - iii. According to the information and explanations given to us, the following are the undisputed statutory dues which are in arrears as at 31<sup>st</sup> March, 2017 for a period of more than six months from the date on which they have become payable.

Nature of Statute	Nature of dues	Amount (Rs. in Lakhs)	Period which the amount relates to	Remarks
The Employees' Provident Funds And Miscellaneous Provisions Act, 1952	Provident Fund	93.17	Nov 2013 to Sep 2016	Not deposited
Employees' State Insurance Act, 1948	ESI	2.61	Apr 2016 & Sep 2016	Not deposited
The Finance Act, 1994	Service Tax	4.57	Apr 2016 & Sep 2016	Not deposited
Income Tax Act, 1961	Tax Deducted at Source	1.04	Apr 2016 & Sep 2016	Not deposited

b) According to the information and explanation given to us, there are no dues of income tax, sales tax, service tax, duty of customs, duty of excise, value added tax outstanding on account of any dispute.

8) The Company has defaulted in the repayment of dues to banks amounting to Rs.33.35 crores. The company had received a notice under section 13(2) of Securitisation and Reconstruction of Financial Assets and Enforcement of Security Interest Act, 2002 vide their notice No.NPA/SHCPL dated: 15 March 2017.

9) The Company has not raised any money by way of initial public offer, further public offer (including debt instruments) during the year. Accordingly, the provisions of Clause 3(ix) of the Order are not applicable to the Company.

10) According to the information and explanations given to us, no material fraud by the Company or on the Company by its officers or employees has been noticed or reported during the course of our audit.

11) According to the information and explanations give to us and based on our examination of the records, the Company has paid/provided for managerial remuneration in accordance with the requisite approvals mandated by the provisions of section 197 read with Schedule V to the Act.;

12) In our opinion and according to the information and explanations given to us, the Company is not a nidhi company. Accordingly, paragraph 3(xii) of the Order is not applicable.

13) According to the information and explanations given to us and based on our examinations of the records of the Company, transactions with the related parties are in compliance with sections 177 and 188 of the Act, where applicable. The details of such related party transactions have been disclosed in the financial statements as required under Accounting Standard (AS) 18, Related Party Disclosures specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.

14) According to the information and explanations give to us and based upon the audit procedures performed and the information and explanations given by the management, the company has not made any preferential allotment or private placement of shares or fully or partly convertible debentures during the year under review. Accordingly, the provisions of clause 3 (xiv) of the Order are not applicable to the Company.

15) According to the information and explanations give to us and based upon the audit procedures performed and the information and explanations given by the management, the company has not entered into any non-cash transactions with any director or persons connected with him. Accordingly, the provisions of clause 3 (xv) of the Order are not applicable to the Company.

16) In our opinion, the company is not required to be registered under section 45-IA of the Reserve Bank of India Act, 1934. Accordingly, the provisions of clause 3 (xvi) of the Order are not applicable to the Company.

For Jayant & Sadashiv  
Chartered Accountants  
Firm Regn. No: 001297S

Jayant Palnitkar  
Partner  
Membership No.020851

Place: Hyderabad  
Date: 30<sup>th</sup> May, 2017

**“Annexure B” to the Independent Auditors’ Report of even date on the Financial Statements of Sangam Health Care Products Limited**

**Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 (“the Act”)**

We have audited the internal financial controls over financial reporting of Sangam Health Care Products Limited (“the Company”) as of March 31, 2017 in conjunction with our audit of the financial statements of the Company for the year ended on that date.

**Management’s Responsibility for Internal Financial Controls**

The Company’s management is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting issued by the Institute of Chartered Accountants of India. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company’s policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

**Auditors’ Responsibility**

Our responsibility is to express an opinion on the Company’s internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the “Guidance Note”) and the Standards on Auditing, issued by ICAI and deemed to be prescribed under section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls, both applicable to an audit of Internal Financial Controls and, both issued by the Institute of Chartered Accountants of India. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditors’ judgement, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls system over financial reporting.

### **Meaning of Internal Financial Controls Over Financial Reporting**

A company's internal financial controls over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial controls over financial reporting includes those policies and procedures that

- (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company;
- (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorisations of management and directors of the company; and
- (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

### **Inherent Limitations of Internal Financial Controls over Financial Reporting**

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

### **Opinion**

In our opinion, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at March 31, 2017, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

For Jayant & Sadashiv  
Chartered Accountants  
Firm Registration. No: 001297S

Jayant Palnitkar  
Partner  
Membership No.020851

Place: Hyderabad  
Date: 30<sup>th</sup> May, 2017

**FORM NO. MR-3  
SECRETARIAL AUDIT REPORT  
FOR THE FINANCIAL YEAR ENDED MARCH 31, 2017.**

[Pursuant to section 204(1) of the Companies Act, 2013 and rule no.9 of the Companies  
(Appointment and Remuneration of Managerial Personnel) Rules, 2014]

To  
The Members  
Sangam Health Care Products Limited,  
205 & 206, Amarchand Sharma Complex  
S P Road, Secunderabad - 2, Telangana

We have conducted the Secretarial Audit of the compliance of applicable statutory provisions and the adherence to good corporate practices by M/s. Sangam Health Care Products Limited (hereinafter called the "**Company**"). Secretarial Audit was conducted in a manner that provided us a reasonable basis for evaluating the corporate conducts/ statutory compliances and expressing our opinion thereon.

Based on our verification of the Company's books, papers, minute books, forms and returns filed and other records maintained by the Company and also the information provided by the Company, its officers, agents and authorized representatives during the conduct of Secretarial Audit, we hereby report that in our opinion, the Company has, during the audit period covering the financial year ended on March 31, 2017 has complied with the statutory provisions listed hereunder and also that the Company has proper Board-processes and compliance-mechanism in place to the extent, in the manner and subject to the reporting made hereinafter:

We have examined the books, papers, minute books, forms and returns filed and other records maintained by the Company for the financial year ended on March 31, 2017 according to the provisions of:

- i. The Companies Act, 2013 (the Act) and the rules made there under;
- ii. The Securities Contracts (Regulation) Act, 1956 ('SCRA') and the rules made there under;
- iii. The Depositories Act, 1996 and the Regulations and Bye-laws framed there under;
- iv. Foreign Exchange Management Act, 1999 and the rules and regulations made there under to the extent of Foreign Direct Investment; **(Not applicable to the Company during the Audit Period);**
- v. The following Regulations and Guidelines prescribed under the Securities and Exchange Board of India Act, 1992 ('SEBI Act'):-



- a) The Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011;
- b) The Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015;
- c) The Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“ Listing Regulations”)
- d) The Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2009; **(Not applicable to the Company during the Audit Period);**
- e) The Securities and Exchange Board of India (Employee Stock Option Scheme and Employee Stock Purchase Scheme) Guidelines, 1999 and The Securities and Exchange Board of India (Share Based Employee Benefits) Regulations, 2014 ; **(Not applicable to the Company during the Audit Period);**
- f) The Securities and Exchange Board of India (Issue and Listing of Debt Securities) Regulations, 2008; **(Not applicable to the Company during the Audit Period);**
- g) The Securities and Exchange Board of India (Registrars to an Issue and Share Transfer Agents) Regulations, 1993 regarding the Companies Act and dealing with client; **(Not applicable to the Company during the Audit Period);**
- h) The Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2009; **(Not applicable to the Company during the Audit Period);** and
- i) The Securities and Exchange Board of India (Buyback of Securities) Regulations, 1998; **(Not applicable to the Company during the Audit Period).**

We have also examined compliance with the applicable clauses of the following:

- i. Secretarial Standards issued by The Institute of Company Secretaries of India.
- ii. The Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Trading of shares suspended with BSE Limited in the year 2001.

During the period under review, the Company has complied with the provisions of the Act, Rules, Regulations, Guidelines, etc. mentioned above subject to the following observations:

- a) Pursuant to the provisions of the section 203(1)(ii) of the Companies Act, 2013 the Company shall appoint company Secretary. However the Company has not complied with the requirement, the post of Company Secretary (KMP) is lying vacant till date.
- b) Company is having electronic connectivity with Central Depository Services Limited (CDSL) only but not with National Securities Depository Limited (NSDL).

- c) Delay in submission of information/filing of documents with BSE Limited pursuant to the Listing Regulations.
- d) Non payment of listing fees to BSE Limited
- e) 100% holding of promoters are not in demat mode.

We further report that the Board of Directors of the Company is not duly constituted with proper balance of Executive Directors, Non-Executive Directors and Independent Directors. The changes in the composition of the Board of Directors that took place during the period under review were carried out in compliance with the provisions of the Act.

Notice was given to all Directors in advance to schedule the Board Meetings. Agenda and detailed notes on agenda were sent in advance, and a system exists for seeking and obtaining further information and clarifications on the agenda items before the meeting and for meaningful participation at the meeting.

All decisions at Board Meetings and Committee Meetings are carried out unanimously as recorded in the minutes of the meetings of the Board of Directors or Committee of the Board, as the case may be.

Relying on the representation given by the Company and its officers with regard to the Other laws applicable specifically to the Company and its Compliance and the limited review done by us, we opine that the Company has generally complied with the following laws to the extent specifically applicable the company:

- (a) Drugs and Cosmetics Act, 1940 and Rules made thereunder;
- (b) Drugs Price Control Order, 2013 and notifications made thereunder

We further report that there are adequate systems and processes in the Company commensurate with the size and operations of the Company to monitor and ensure compliance with applicable laws, rules, regulations and guidelines.

For R & A Associates

Place: Hyderabad  
Date: September 01, 2017

P. Surya Prakash  
Membership No: 9072 CP No. 11142

To,

The Members  
Sangam Health Care Products Limited,  
205 & 206, Amarchand Sharma Complex  
S P Road, Secunderabad - 2, Telangana

Our report of even date is to be read along with this letter:

1. Maintenance of secretarial records is the responsibility of the management of Sangam Health Care Products Limited, (**"the Company"**). Our responsibility is to express an opinion on these secretarial records based on our audit.
2. We have followed the audit practices and processes as were appropriate to obtain reasonable assurance about the correctness of the contents of the Secretarial records. The verification was done on test basis to ensure that correct facts are reflected in secretarial records. We believe that the processes and practices, we followed provide a reasonable basis for our opinion.
3. We have not verified the correctness and appropriateness of financial records and Books of Accounts of the Company.
4. Where ever required, we have obtained the Management representation about the compliance of laws, rules and regulations and happening of events etc.
5. The compliance of the provisions of Corporate and other applicable laws, rules, regulations, standards is the responsibility of management. Our examination was limited to the verification of procedures on test basis.
6. The Secretarial Audit report is neither an assurance as to the future viability of the Company nor of the efficacy or effectiveness with which the management has conducted the affairs of the Company.
7. With regards to various submission(s) of information / document and compliance thereof made by the company with the stock exchanges, the reporting of compliance was made based upon the information / documents available. However, some of the information and documents were not available for verification.

For R & A Associates

Place: Hyderabad  
Date: September 01, 2017

P. Surya Prakash  
Membership No: 9072 CP No. 11142

**CORPORATE GOVERNANCE REPORT**

In compliance with Regulation 34(3) read with schedule V of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations, 2015"), the Company submits the Corporate Governance Report for the year ended 31st March, 2017.

**1. COMPANY'S PHILOSOPHY ON CORPORATE GOVERNANCE:**

Sangam Health Care Products Limited's (SANGAM) philosophy on Corporate Governance envisages working towards high levels of transparency, accountability, consistent value systems, delegation across all facets of its operations leading to sharply focused and operationally efficient growth. The Company tries to work by these principles in all its interactions with stakeholders, including shareholders, employees, customers, suppliers and statutory authorities.

SANGAM is committed to learn and adopt the best practices of Corporate Governance.

**2. BOARD OF DIRECTORS:**

The Board of Directors along with the Committees of the Board, provides leadership and guidance to the Company's Management and directs, supervises and controls the activities of the Company. The Board of the Company is represented by well-known people from different walks of life. They are reputed and successful professionals, businessmen having expert knowledge of finance and industry.

They are well recognized in the society for their contributions and achievements in their respective fields of expertise.

**a) Composition:**

As on 31 March 2017, the Board of the Company consisted of eight directors, of whom one was executive (Managing Director), two non-executive independent and five were non-executive and non-independent (including one-woman director). The Board has no institutional nominee director. The Company has an Executive Chairman. According to regulation 17(1)(b) of SEBI (LODR) Regulations, 2015, where the chairperson of the Board is a executive director, at least half of the Board of directors shall comprise of independent directors.

However, Sangam is not complied with the said requirement and the Management is in the process of identifying suitable person to be appointed as Independent Director.

**b) Number of Meetings of the Board:**

During the financial year 2016-17, the Board met six times and the gap between any two meetings has been less than one hundred and twenty days. The Directors who were present in the Board Meeting are marked as "√" and the directors who were granted leave of absence was marked as "X".

Sl No.	Name of Director	May 16, 2016	Aug 12, 2016	Nov 11, 2016	Feb 13, 2017	Feb 21, 2017
1.	Khushwant Singh	√	√	√	√	√
2.	Pradyut Waghray	√	√	√	√	√
3.	Bala Gopal Addepalli	√	√	√	√	√
4.	Basawaraj Nagabusappa Sajjan	χ	√	χ	χ	χ
5.	Venkata Subramanya Sharma Devarkonda	χ	√	χ	χ	χ
6.	Ramana Ganakota	χ	√	χ	χ	χ
7.	Padma Ghanakota	√	√	√	√	√
8.	Lingaraj Shantalingappa Patil	χ	χ	χ	χ	χ

**Note:**

Mr. Venkata Subramanya Sharma Devarkonda and Mrs. Ramana Ganakota resigned from directorship w.e.f. Feb 17, 2017 and Mr. Lingaraj Shantalingappa Patil has not attended any meeting during the year under review as he has tendered his resignation on Feb 28, 2015; however, Company has yet to decide on acceptance of the same.

**C. Attendance Record of Directors****Table - I**

Name of the Director	Category and Position	No. of Board Meetings		Whether attended last AGM	No. of Committees of Board of other companies		No. of other Directorship held
		Held	Attended		Chairmanship	Member	
Bala Gopal Addepalli	Chairman and Managing Director	5	5	Yes	-	-	1
Khushwant Singh	Non-Executive & Independent	5	5	Yes	-	-	-
Pradyut Waghray	Non-Executive & Independent	5	5	Yes	-	-	2
Venkata Subramanya Sharma Devarkonda	Non-Executive	5	1	No	-	-	-
Basawaraj Nagabusappa Sajjan	Non-Executive	5	1	No	-	-	-
Ramana Ganakota	Non-Executive	5	1	Yes	-	-	-
Padma Ghanakota	Non-Executive	5	5	Yes	-	-	-
Lingaraj Shantalingappa Patil	Non-Executive	5	-	No	-	-	-

Note: Mr. Venkata Subramanya Sharma Devarkonda and Mrs. Ramana Ganakota resigned from directorship w.e.f. Feb 17, 2017 and Mr. Lingaraj Shantalingappa Patil has not attended any meeting during the year under review as he has tendered his resignation on Feb 28, 2015; however, Company has yet to decide on acceptance of the same.

**d) Disclosure of relationship between directors inter-se:** No non-executive directors have any material pecuniary relationship or transactions with the company, its promoters or its management, which in the judgment of the board may affect independence of judgment of the director.

**e) Committees of the Board**

The Board has constituted Committees with specific terms of reference/scope to focus effectively on issues and ensure expedient resolution of diverse matters.

At present, the Company has the following Board Level Committees, namely:

A) Audit Committee

B) Remuneration Committee

C) Shareholders/Investor's Grievance Committee

☞ The Compliance officer acts as the Secretary of all the aforementioned Committees.

☞ The minutes of the meetings of all Committees of the Board are placed before the Board for discussions / noting.

**3. AUDIT COMMITTEE:**

In terms of Listing Regulations and Section 177 of the Companies Act, 2013, the Board has an Audit Committee comprising of Mr. Khushwant Singh [Chairman], Mr. Pradyut Waghray all Independent Directors and Mr. Bala Gopal Addepalli Managing Director as members.

All members of the Committee are financially literate. Section 177 of the Act has enlarged the scope of Audit Committee. Now, the terms of reference of the Audit Committee has been specified in the Act. The Audit Committee, inter alia advises the management on the areas where systems, processes, measures for controlling and monitoring revenue assurance, internal audit and the risk management can be improved. The minutes of the meetings of the Audit Committee are placed before the Board.

**Attendance at the meetings of the Audit Committee held during 2016-17:**

The Audit Committee held its meetings on (i) May 16, 2016, (ii) August 12, 2016, (iii) November 11, 2016 and (iv) February 13, 2017. The meetings were scheduled well in advance and the maximum time gap between any two meetings was 93 days and the minimum gap was 87 days

S.No.	Name of the Director	Category	Meetings Held	Meetings Attended
1	Khushwant Singh	Chairman, Non - executive, Independent	4	4
2	Pradyut Waghray	Non -executive, Independent	4	4
3	Bala Gopal Addepalli	Executive	4	4

**4. NOMINATION & REMUNERATION COMMITTEE:**

The Nomination and Remuneration Committee in terms of Section 178 of the Companies Act, 2013 and Listing Regulations comprises of three (3) directors, viz; Mr. Khushwant Singh [Chairman], Mr. Pradyut Waghray and Mrs. Padma Ghanakota as members.

- i. Mrs. Padma Ghanakota was appointed as a member of Nomination & Remuneration Committee in the Board Meeting dated February 13, 2017 ; in place of Mr. Basawaraj Nagabusappa Sajjan who showed his inability to continue as the member of the Committee
- ii. No meeting of the Nomination and Remuneration Committee was held during the financial year 2016-17.
- iii. The Managing/Executive Directors are not paid any remuneration during the financial year under review. The Non-Executive Director did not draw any remuneration from the Company except sitting fees for each meeting of the Board attended by them
- iv. Remuneration Policy as per Annexure-II

**5. STAKEHOLDERS RELATIONSHIP COMMITTEE:**

In accordance with the requirements of Listing Regulations and provisions of the Act, the Company has constituted "Stakeholders Relationship Committee" to resolve the grievances of all the stakeholders of the Company and to perform all other work. The Committee has three (3) six members consisting of Mr. Khushwant Singh [Chairman], Mr. Pradyut Waghray and Mr. Bala Gopal Addepalli as members.

Attendance at the meetings of Stakeholders Relationship Committee held during 2016-17. During the year, the Stakeholder's Relationship Committee held its meetings on (i) May 16, 2016, (ii) August 12, 2016, (iii) November 11, 2016 and (iv) February 13, 2017. The meetings were scheduled well in advance and the maximum time gap between any two meetings was 93 days and the minimum gap was 87 days

S.No.	Name of the Director	Category	Meetings Held	Meetings Attended
1	Bala Gopal Addepalli	Chairman, Executive	4	4
2	Basawaraj Nagabusappa Sajjan	Non- executive	4	4

- i. Mr. Khushwant Singh and Mr. Pradyut Waghray were appointed as a members in Stakeholders relationship committee in the Board Meeting dated February 13, 2017 ; in place of Mr. Basawaraj Nagabusappa Sajjan who showed his inability to continue as the member of the Committee
- ii. There were no complaints received from the shareholders during the year ended March 31, 2017

- iii. The Company ensures that the investor's correspondence is attended expeditiously and endeavour is made to send a satisfactory reply within ten days of receipt, except in cases that are constrained by disputes or legal impediments.
- iv. There are no pending share transfer complaints as on March 31, 2017.

**COMPLIANCE OFFICER:** Mr. G S R Murthy

As on 31st March, 2017 - 8,01,800 (5.40%) Shares are in demat accounts with Central Depository Services (India) Limited and 14056900 (94.60%) shares in physical.

## 6. GENERAL BODY MEETING:

a) Location and time of the Annual General Meetings of the company

AGM	Financial Year	Day/Date	Time	Venue	Special Resolutions
22 <sup>nd</sup>	2015-16	30-09-2016	3.00 P.M	205 & 206, Amarchand Sharma Complex, S.P. Road, Secunderabad- 500003	Nil
					1. Material Related Party contract with M/s Sri Sai Gravure Prints
					2. Material Related Party contract with M/S Sri Sai Health Care Products
					3. Borrow money in excess of paid-up share capital and free reserves
21 <sup>st</sup>	2014-15	28-09-2015	3.30 P.M		4. Secure the money borrowed in excess of paid-up share capital and free reserves
20 <sup>th</sup>	2013-14	30-09-2014	3.30 A.M		Nil

### b. Postal Ballot Resolution

No Postal ballot resolution was passed during the year ended March 31, 2016. No special resolution requiring a postal ballot is being proposed for the ensuing Annual General Meeting.

c. Details of Extra-Ordinary General Meetings held during the year: Nil

## 8. MEANS OF COMMUNICATION:

- ☞ The Quarterly, half-yearly and annual results of the Company's performance are sent to the BSE Limited.



- ☞ The company's website address is: www.sangamhealthcare.co.in. The website contains basic information about the company. The company ensures periodical updation of its website. The company has designated the email-id sangamlisting@gmail.com in to enable the shareholders to register their grievances.
- ☞ The Company has 650 shareholders as on 31st March, 2017. The Company mainly communicates with its shareholders through Annual Report, which includes the Director's Report, Management Discussion and Analysis Report, Report on Corporate Governance.
- ☞ No presentations have been made to institutional investors or to analysts

## 9. **GENERAL SHAREHOLDER INFORMATION:**

### a) **23<sup>rd</sup> Annual General Meeting:**

Date: 29<sup>th</sup> September, 2017

Time: 3 P.M.

Venue: Registered office

b) **Financial Year** : 1<sup>st</sup> April, 2016 to 31<sup>st</sup> March, 2017

c) **Date of Book Closure** : Sept. 23, 2017 to September 29, 2017  
(both days inclusive)

d) **Dividend Payment Date** : No

e) **Financial Calendar** : For the FY 2017-18

Financial Results	Cut-off Date
Unaudited first quarter financial results	On or before August 14, 2017
Unaudited second quarter financial results	On or before November 14, 2017
Unaudited third quarter financial results	On or before February 14, 2018
Approval of audited annual results for year ending 31 March, 2017	On or before May 30, 2018

### f) **Listing on Stock Exchange:**

Name of the Stock Exchange	Address	Scrip Code/Scrip ID
Bombay Stock Exchange Limited (BSE)	25 <sup>th</sup> Floor, P.J. Towers, Dalal Street, Mumbai -400001	531625 SANHP

The Company has not paid listing fees to BSE for the year 2017-18.

g) **ISI Number for NSDL & CDSL** : INE431E01011

### h) **Depositories**

i. **Central Depository Services (India) Ltd.,**

Phiroze Jeejeebhoy Towers, 28th Floor, Dalal Street, Mumbai-400023.

### i) **Market Price Data :**

The Company's shares are not being traded in BSE Limited. Hence, information regarding the market price could not be provided.

**j) Registrar & Share Transfer Agent:**

For lodgement of transfer deeds and other documents or for any grievances/ complaints, investors may contact the Company's Registrar and Share Transfer Agent at the following address:

**M/S XL SOFTECH SYSTEMS LTD.**

3, Sagar Society, Road No. 2, Banjara Hills, Hyderabad-500034.

Phone # 040-23545913/14/15, Email: xlfield@rediffmail.com

**k) Share Transfer System:**

The Board of Directors of the Company has delegated the powers of share transfers, splitting, consolidation of share certificates and issue of duplicate shares, rematerialisation of shares etc. to Share Transfer Committee. The board attends the share transfer formalities at least once in a fortnight. The Registrar and Share Transfer Agents register the shares received for transfer in physical mode, within 15 days from the date of lodgement, if documents are complete in all respects.

**l) Shareholding Pattern as on 31<sup>st</sup> March, 2017:**

Sl. No.	Category share holders	No. of Share held issued shares	No. of of Total	Percentage
1	Promoters	6	10421040	70.12
2	Mutual Fund	3	599100	4.03
3	Banks/FI	5	653900	4.40
4	Private Corporate Bodies	7	1598160	10.75
5	Public	626	1578500	10.62
6	Others	3	10000	0.07
	<b>Total</b>	<b>650</b>	<b>14860700</b>	<b>100.00%</b>

**m) Dematerialization of Shares & Liquidity:**

The Company's shares are available for trading in the depository systems with the Central Depository Services (India) Limited (CDSL) and as on 31st March, 2017, 801800 (5.40%) Equity Shares are in demat accounts with Central Depository Services (India) Limited.

**n) Reconciliation of Share Capital Audit:**

The Reconciliation of Share Capital Audit was carried out by Practicing Company Secretary for each of the quarters in the financial year 2016-17, to reconcile the admitted capital with Central Depository Services (India) Limited (CDSL) and total issued and listed capital. The audit reports confirm that the total issued/ paid-up capital is an agreement with the total number of shares in physical form and the total number of dematerialized shares held with depositories.

- o) Outstanding GDRs/ADRs/Warrant or any convertible instruments:**  
The Company has not issued any GDRs/ADRs, Warrants or any convertible instruments.
- p) Commodity price risk or foreign exchange risk and hedging activities:**  
The Company monitors the price of key commodities closely and formulates the procurement strategies basis actual price movements / trends / projections in India. The Company has adequate governance structure of aligning and reviewing the procurement strategies in line with external and internal dynamics.
- q) Address for Correspondence:**  
For queries relating to financial statements, please write to:  
**SANGAM HEALTH CARE PRODUCTS LTD**  
Regd.Off.: 205,206, Amarchand Sharma Complex S.P. Road, Secunderabad - 500002.
- e) Website:** www.sangamhealthcare.co.in  
It is also affirmed that no member has been denied access to the Audit Committee.

**9. DISCRETIONARY REQUIREMENTS:**

The Company is complying with the following discretionary requirements prescribed under Schedule II Part E of the SEBI (LODR) Regulations, 2015:

1. Separate posts of Chairman and Managing Director: The Company has not complied with the said requirement as Mr. Bala Gopal Addepalli is holding both the post as chairman and Managing Director.
2. Reporting of Internal Auditor: The Internal Auditor of the company directly reports to the Audit Committee
3. Independent Directors possess the requisite qualification and experience to contribute effectively to the company in their capacity as independent director
4. The statutory financial statements of the company are unqualified

**DECLARATION FOR CODE OF CONDUCT**

As required under Part D of Schedule V of SEBI (LODR) Regulations, 2015, it is hereby declared that the Company has obtained confirmation from all the Board Members and Senior Management Personnel of the Company for the compliance of the Code of Conduct of the Company for the year ended on 31st March, 2017.

Date : Sept 05, 2017  
Place : Secunderabad

Sd/-  
(A Bala Gopal)  
Managing Director  
(DIN: 01712903)

**ANNEXURE - VI**

**Form No. MGT-9**  
**EXTRACT OF ANNUAL RETURN**  
**as on the financial year ended on 31st March, 2017**  
**[Pursuant to section 92(3) of the Companies Act, 2013 and rule 12(1) of the**  
**Companies (Management and Administration) Rules, 2014]**

**I. REGISTRATION AND OTHER DETAILS:**

- i. **CIN** : L24230TG1993PLC016731
- ii. **Registration date** : 12/13/1993
- iii. **Name of the Company** : SANGAM HEALTH CARE PRODUCTS LTD
- iv. **Category/Sub Category of the Company** : Company Limited by Shares/  
Indian Non-Government Company
- v. **Address of the Registered Office and Contact details** : 205, 206, Amarchand Sharma Complex,  
S.P. Road, Secunderabad - 500002,  
Telangana
- vi. **Whether Listed Company** : Yes
- vii. **Name, Address and contact details of Registrar and Transfer Agent, if any** : M/s. XL Softech Systems Limited3,  
Sagar Society, Road No.2,  
Banjara Hills, Hyderabad  
Tel : 040-23545913, 23545914, 23545915  
e-mail: xlfield@rediffmail.com

**II. PRINCIPAL BUSINESS ACTIVITIES OF THE COMPANY:**

All the business activities contributing 10% or more of the total turnover of the Company shall be stated:

Sl. No.	Name and Description of main products / services	NIC Code of the Product/ service	% to total turnover of the company
1.	Other human health activities n.e.c.	86909	99.49%

**III. PARTICULARS OF HOLDING, SUBSIDIARY AND ASSOCIATE COMPANIES: NIL**

S. No	Name and address of the Company	CIN/ GLN	Holding/ subsidiary /Associate	% of shares held	Applicable section
	Nil				

IV. SHARE HOLDING PATTERN (Equity Share Capital Breakup as percentage of Total Equity)									
i) CATEGORY-WISE SHARE HOLDING									
Category of Shareholders	No. of Shares held at the beginning of the year				No. of Shares held at the end of the year				% Change during the year
	Demat	Physical	Total	% of Total Shares	Demat	Physical	Total	% of Total Shares	
<b>A. PROMOTERS</b>									
<b>(1) INDIAN</b>									
a) Individual/HUF	-	10421030	10421030	70.12	-	10421030	10421030	70.12	-
b) Central Govt.	-	-	-	-	-	-	-	-	-
c) State Govt.	-	-	-	-	-	-	-	-	-
d)Bodies Corporate	-	-	-	-	-	-	-	-	-
e)Bank/FI's	-	-	-	-	-	-	-	-	-
f) Any Other	-	-	-	-	-	-	-	-	-
<b>Sub-Total (A)(1):-</b>	-	<b>10421030</b>	<b>10421030</b>	<b>70.12</b>	-	<b>10421030</b>	<b>10421030</b>	<b>70.12</b>	-
<b>(2) Foreign</b>									
a) NRI's- Individuals	-	-	-	-	-	-	-	-	-
b) Other Individuals	-	-	-	-	-	-	-	-	-
c)Bodies Corporate	-	-	-	-	-	-	-	-	-
d)Bank/FI's	-	-	-	-	-	-	-	-	-
e) Any Other	-	-	-	-	-	-	-	-	-
<b>Sub-Total (A)(2):-</b>	-	-	-	-	-	-	-	-	-
<b>Total Shareholding of Promoter (A)= (A)(1)+(A)(2)</b>	-	<b>10421030</b>	<b>10421030</b>	<b>70.12</b>	-	<b>10421030</b>	<b>10421030</b>	<b>70.12</b>	-

<b>B) PUBLIC SHAREHOLDING</b>									
<b>1. INSTITUTIONS</b>									
a) Mutual Funds	-	599,100	599,100	4.03	200000	399100	599100	4.03	-
b) Banks/FI's	-	-	-	-	-	-	-	-	-
c) Central Govt.	-	-	-	-	-	-	-	-	-
d) State Govt.	-	-	-	-	-	-	-	-	-
e) Venture Capital Funds	-	-	-	-	-	-	-	-	-
f) Insurance Companies	400,000	253,900	653,900	4.40	400000	253900	653900	4.40	-
g) FII's	-	-	-	-	-	-	-	-	-
h) Foreign Venture Capital	-	-	-	-	-	-	-	-	-
i) Others (Specify)	-	-	-	-	-	-	-	-	-
<b>Sub-Total (B)(1):-</b>	<b>400,000</b>	<b>853,000</b>	<b>1,253,000</b>	<b>8.43</b>	<b>600000</b>	<b>653000</b>	<b>1253000</b>	<b>8.43</b>	<b>-</b>
<b>2. NON-INSTITUTIONS</b>									
a) Bodies Corporate	-	-	-	-	-	-	-	-	-
i) Indian	-	1,598,160	1,598,160	10.76	-	1598160	1598160	10.75	-
ii) Overseas	-	-	-	-	-	-	-	-	-
b) Individuals	-	-	-	-	-	-	-	-	-
i) Individual Shareholders holding nominal share capital in upto of Rs. 2 Lakh	13200	807510	820710	5.52	13200	807510	820710	5.52	-
ii) Individual Shareholders holding nominal share capital in excess of Rs. 2 Lakh	188600	569200	757800	5.10	188600	569200	757800	5.10	-
c) Others (NRIs Repatriable)	-	10000	10000	0.07	-	10000	10000	0.07	-
<b>Sub-Total (B)(2):-</b>	<b>201800</b>	<b>2984870</b>	<b>3186670</b>	<b>21.45</b>	<b>201800</b>	<b>2984870</b>	<b>3186670</b>	<b>21.45</b>	<b>-</b>
<b>Total Public Shareholding (B)=(B)(1)+(B)(2)</b>	<b>601800</b>	<b>3837870</b>	<b>4439670</b>	<b>29.88</b>	<b>601800</b>	<b>3837870</b>	<b>4439670</b>	<b>29.88</b>	<b>-</b>
<b>C. Shares held by Custodians for ADR's &amp; GDR's</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>

## ii) SHAREHOLDING OF PROMOTERS

S. No	Shareholder's Name	Shareholding at the beginning of the year			Shareholding at the end of the year			% change in share holding during the year
		No. of Shares	% of total Shares of the company	% of Shares Pledged / encumbered to total	No. of Shares	% of total Shares of the company	% of Shares Pledged / encumbered to total	
1	Addepalli Bala Gopal	3001000	20.19	-	3001000	20.19	-	-
2	Devarakonda venkata S. Sharma	2500000	16.82	-	2500000	16.82	-	-
3	Ganakota Padma	2000000	13.46	-	2000000	13.46	-	-
4	Ganakota Ramana	2255140	15.18	-	2255140	15.18	-	-
5	Devarakonda V S Krishna Teja	379900	2.56	-	379900	2.56	-	-
6	Sai Balaji Krishna Teja Addepalli	284900	1.92	-	284900	1.92	-	-
<b>Total</b>		<b>10420940</b>	<b>70.12</b>	-	<b>10420940</b>	<b>70.12</b>	-	-

(iii) CHANGE IN PROMOTERS' SHAREHOLDING: NIL

**(iv) SHAREHOLDING PATTERN OF TOP TEN SHAREHOLDERS (OTHER THAN DIRECTORS, PROMOTERS AND HOLDERS OF GDRS AND ADRS):**

S.No.	Shareholder's Name	Shareholding at the beginning of the year		Shareholding at the end of the year	
		No. of Shares	% of Total Shares of the Company	No. of Shares	% of Total Shares of the Company
1	M/S Boin Medica Co Limited	1240260	8.35	1240260	8.35
2	UTI AMC Pvt.Limited.	300000	2.02	300000	2.02
3	Shobha Bembolgi	260000	1.75	260000	1.75
4	Principal Trustee Company Pvt Limited.	200000	1.35	200000	1.35
5	Dundumulla Bhagat Reddy	-	-	200000	1.35
6	Bank of India	19970	1.34	19970	1.34
7	GIC Asset Management Company Limited	199400	1.34	199400	1.34
8	Indian Bank	150000	1.01	150000	1.01
9	Ajay Kumar Kayan	142500	0.96	142500	0.96
10	SMIFS Capital Markets Limited	142400	0.96	142400	0.96

**(v) SHAREHOLDING OF DIRECTORS AND KEY MANAGERIAL PERSONNEL:**

S.No.	Shareholder's Name	Shareholding at the beginning of the year		Cumulative Shareholding during the year	
		No. of Shares	% of Total Shares of the Company	No. of Shares	% of Total Shares of the Company
1	<b>Addepalli Bala Gopal</b>				
	At the beginning of the year	3,001,000	20.19	-	0
	Increase in Shareholding during the year	-	-	-	-
	At the end of the year	3,001,000	20.19	3,001,000	20.19
2	<b>Ganakota Padma</b>				
	At the beginning of the year	2,000,000	13.46	-	0
	Increase in Shareholding during the year	-	-	-	-
	At the end of the year	2,000,000	13.46	2,000,000	13.46



**V. INDEBTNESS:** Indebtedness of the Company including interest outstanding/accrued but not due for payment

	Secured Loans excluding deposits	Unsecured Loans	Deposits	Total Indebtedness
Indebtedness at the beginning of the financial year				
i) Principal Amount	289504569	48843496	-	338348065
ii) Interest due but not paid	5145000	-	-	5145000
iii) Interest accrued but not due	-	-	-	-
<b>Total (i+ii+iii)</b>	<b>294649569</b>	<b>48843496</b>	-	<b>343493065</b>
Changes in Indebtedness during the year				
Addition	60000000	1538224	-	61538224
Redution	21166663	-	-	21166663
Net Change	38833337	1538224	-	40371561
Indebtedness at the end of the financial year				
i) Principal Amount	313314879	50381720	-	363696599
ii) Interest due but not paid	20168027	-	-	20168027
iii) Interest accrued but not due	-	-	-	-
<b>Total (i+ii+iii)</b>	<b>333482906</b>	<b>50381720</b>	-	<b>383864626</b>

**VI. REMUNERATION TO DIRECTORS AND KEY MANAGERIAL PERSONNEL:**

A. Remuneration to Managing Director, Whole-Time Director and/or Manager: Nil

B. Remuneration to other Directors: Nil

C. Remuneration to Key Managerial Personnel Other than MD/MANAGER/WTD: Nil

**VII. PENALTIES/PUNISHMENT/COMPOUNDING OF OFFENCES:** Nil

**ANNEXURE - VII****CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION AND FOREIGN EXCHANGE OUTGO:**

Information on Conservation of Energy, technology absorption, foreign exchange earnings and outgo required to be given pursuant to Section 134 (3) (m) of the Companies Act, 2013, read with the Rule 8 of Companies (Accounts) Rules, 2014 is not applicable since there is no such activity at present being pursued by the Company.

**A. CONSERVATION OF ENERGY**

i)	The steps taken or impact on conservation of energy	Company's operations are not energy intensive. Adequate measures have been taken to conserve energy wherever possible by using effective equipment.
ii)	The steps taken by the Company for utilizing alternate sources of energy	Nil
iii)	The capital investment on energy conservation equipments	Nil

**B. TECHNOLOGY ABSORPTION**

i)	The efforts made towards technology absorption	The Company has adapted indigenous technology and innovated upon the same.
ii)	The benefits derived like product improvement, cost reduction, product development or import substitution	Product improvement, increase in yield, production of high value added products.
iii)	In case of imported technology (imported during the last three years reckoned from the beginning of the financial year)	No technology has been imported during the last three years.
	The details of technology imported	NA
	The year of import	NA
	Whether the technology been fully absorbed	NA
iv)	If not fully absorbed, areas where absorption has not taken place and the reasons thereof and	NA
	The expenditure incurred on Research and Development	Expenditure on in-house Research & Development was not incurred during the year under review.

**C. FOREIGN EXCHANGE EARNINGS AND OUTGO**

i) Foreign Exchange Earned:	2016-17	2015-16
FOB value of exports	Nil	Nil
CIF value of exports	Nil	Nil
ii) Foreign Exchange used:		
Commission on Exports	Nil	Nil
Foreign Travel Expenses	Nil	Nil
Spare parts	Nil	Nil

**CERTIFICATION BY MD & CFO OF THE COMPANY**

(Regulation 17(8) of SEBI (LODR) Regulations, 2015 read with PART B of Schedule II)

We, Bala Gopal Addepalli, Managing Director and Satish Kumar Varre, Chief Financial Officer of Sangam Health Care Products Limited, to the best of our knowledge and belief certify that :

1. We have reviewed the Balance Sheet, Statement of Profit and Loss, its notes to the accounts and Cash Flow Statement for the year ended 31<sup>st</sup> March, 2016 and that to the best of our knowledge and belief :
  - a) these statements do not contain any materially untrue statement or omit any material fact or contain statements that might be misleading;
  - b) these statements together present a true and fair view of the Company and are in compliance with existing accounting standards, applicable laws and regulations.
2. We also certify that, based on our knowledge and the information provided to us, there are no transactions entered into by the Company during the year which are fraudulent, illegal or violate the Company's code of conduct.
3. We accept the responsibility for establishing and maintaining internal controls for financial reporting and that we have evaluated the effectiveness of internal control systems of the Company pertaining to financial reporting and we have disclosed to the auditors and the Audit Committee, deficiencies in the design or operation of such internal controls, if any, of which we are aware and the steps taken or propose to take to rectify these deficiencies.
4. We have indicated to the Auditors and the Audit Committee :
  - a) significant changes in internal control during the year;
  - b) significant changes in accounting policies during the year and that the same have been disclosed in notes to the financial statements; and
  - c) instances of significant fraud of which we have become aware and the involvement therein, if any, of the management or an employee having a significant role in the company's internal control system.

Date: Sept 05, 2017  
Place: Secunderabad

Sd/-  
Bala Gopal Addepalli  
Managing Director  
DIN: 01712903

Sd/-  
Satish Kumar Varre  
CFO  
PAN: ACLPV7670E

**COMPLIANCE CERTIFICATE FROM AUDITORS REGARDING COMPLIANCE  
OF CONDITIONS OF CORPORATE GOVERNANCE**

[Regulation 34(3) of SEBI (LODR), 2015]

To  
The Members  
**Sangam Health Care Products Limited.**

We have examined the compliance of conditions of Corporate Governance by **Sangam Health Care Products Limited** for the year ended March 31, 2017, as stipulated in Chapter IV of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations).

The Compliance of conditions of Corporate Governance is the responsibility of the management. Our examination was limited to procedures and implementation thereof, adopted by the Company for ensuring the Compliance of the conditions of the Corporate Governance. It is neither an audit nor an expression of opinion on the financial statements of the Company.

In our opinion and to the best of our information to the explanations given to us, we certify that the Company has complied with the conditions of Corporate Governance as stipulated in the above mentioned in Part E of Schedule V of SEBI (LODR) Regulations, 2015 except constitution of Board

We further state that such compliance is neither an assurance as to the future viability of the Company nor the effectiveness with which the management has conducted the affairs of the Company.

For **Jayant & Sadashiv**  
Chartered Accountants

Date : Sept. 05, 2017  
Place: Secunderabad

Sd/-  
Jayant Palnitkar  
Memb. No. 020851

**SANGAM HEALTH CARE PRODUCTS LIMITED****Balance Sheet as at 31st March 2017****(in Rupees)**

	Note No.	As at 31st March 2017	As at 31st March 2016
<b>SOURCES OF FUNDS</b>			
<b>Equity &amp; Liabilities :</b>			
(a) Share capital	2	148,607,000	148,607,000
(b) Reserves and surplus	3	(402,101,261)	(333,534,997)
		<b><u>(253,494,261)</u></b>	<b><u>(184,927,997)</u></b>
<b>Non-current liabilities</b>			
(a) Long-term borrowings	4	309,060,065	278,130,667
(b) Long-term provisions	5	8,367,279	7,976,453
		<b><u>317,427,344</u></b>	<b><u>286,107,120</u></b>
<b>Current liabilities</b>			
(a) Short-term borrowings	6	87,155,443	82,739,131
(b) Trade Payables	7		
Dues to Micro and Small Enterprises		-	-
Dues to Others		55,351,058	76,176,237
(c) Other current liabilities	8	72,778,246	66,565,111
(d) Short-term Provisions	9	84,380	598,706
		<b><u>215,369,127</u></b>	<b><u>226,079,185</u></b>
<b>TOTAL</b>		<b><u>279,302,210</u></b>	<b><u>327,258,307</u></b>
<b>ASSETS</b>			
<b>Non-current assets</b>			
(a) Fixed assets			
Tangible assets	10	214,411,869	226,258,430
(b) Long-term loans and advances	11	14,032,897	13,278,894
		<b><u>228,444,766</u></b>	<b><u>239,537,324</u></b>
<b>Current assets</b>			
(a) Inventories	12	48,254,872	68,475,956
(b) Trade receivables	13	561,802	1,345,948
(c) Cash and cash equivalents	14	1,586,497	17,553,912
(d) Short-term loans and advances	15	454,273	345,167
		<b><u>50,857,444</u></b>	<b><u>87,720,983</u></b>
<b>TOTAL</b>		<b><u>279,302,210</u></b>	<b><u>327,258,307</u></b>
See accompanying notes for the financial statements	1		

As per our Report of even date  
for **JAYANT & SADASHIV**Chartered Accountants  
Firm Reg. No. : 001297S**Jayant Palnitkar**  
Partner

Membership No: 020851

Place : Hyderabad  
Date : 30.05.2017**Bala Gopal Addepalli**  
Managing Director

DIN No. 01712903

**Padma Ganakoa**  
Director

DIN No. 07078176

**V. Satish Kumar**  
C.F.O.

PAN: ACLPV7670E

For and on behalf of the Board of Directors

**SANGAM HEALTH CARE PRODUCTS LIMITED**

**SANGAM HEALTH CARE PRODUCTS LIMITED**  
**PROFIT AND LOSS ACCOUNT** (in Rupees)

Particulars	Note No.	For the year ended	
		31st March 2017 Rs.	31st March 2016 Rs.
Revenue from operations	16	236,169,430	231,637,279
Other income	17	1,200,494	2,747,792
<b>Total Revenue</b>		<b>237,369,924</b>	<b>234,385,071</b>
<b>Expenses:</b>			
Cost of materials consumed	18	109,565,754	103,360,248
Changes in inventories of finished goods and work-in-progress	19	20,131,359	(6,338,887)
Employee benefits expense	20	52,454,561	44,075,490
Finance costs	21	50,486,238	37,999,850
Depreciation & Amortization Expenses	10	15,216,997	15,256,228
Other expenses	22	57,914,998	55,418,193
<b>Total expenses</b>		<b>305,769,907</b>	<b>249,771,122</b>
Loss before Taxes for the year		(68,399,983)	(15,386,051)
(a) Tax of Earlier years		166,281	-
<b>Profit/(Loss) after taxes for the year</b>		<b>(68,566,264)</b>	<b>(15,386,051)</b>
Earnings per equity share:	1. VI		
(1) Basic		(4.61)	(1.04)
(2) Diluted		(4.61)	(1.04)
Weighted average number of equity shares (Face Value of ` 10 each)		14,860,700	14,860,700
The accompanying notes are an integral part of these financial statements	1		

As per our Report of even date  
**for JAYANT & SADASHIV**  
Chartered Accountants  
Firm Reg. No. : 001297S

For and on behalf of the Board of Directors  
**SANGAM HEALTH CARE PRODUCTS LIMITED**

<b>Jayant Palnitkar</b> Partner Membership No: 020851	<b>Bala Gopal Addepalli</b> Managing Director DIN No. 01712903	<b>Padma Ghanakota</b> Director DIN No. 07078176	<b>V. Satish Kumar</b> C.F.O. PAN: ACLPV7670E
---	--	--	---

Place : Hyderabad  
Date : 30.05.2017

**CASH FLOW STATEMENT FOR THE YEAR ENDED 31<sup>ST</sup> MARCH, 2017**

<b>A. CASH FROM OPERATING ACTIVITIES</b>	<b>31.03.17</b>	<b>31.03.16</b>
(Loss)/Profit before tax and extraordinary items	(68,566,264)	(15,386,051)
Adjustment for		
- Depreciation	15,216,997	15,256,228
- Interest & Financial charges	50,486,238	37,999,850
- Interest received	(1,200,494)	(2,747,792)
<b>Operating Profit before Working Capital Changes</b>	<b>(4,063,523)</b>	<b>35,122,235</b>
Adjustment for		
- Trade & Other receivables	784,148	1,217,319
- Inventories	20,221,084	1,577,056
- Trade & others Payable	(14,612,044)	9,495,120
- Short term Loans & Advances	(109,106)	106,984
- Short Term Borrowings & Provisions	3,901,986	(13,261,229)
<b>Cash flow before Extraordinary items</b>	<b>6,122,545</b>	<b>34,257,485</b>
- Interest paid	(50,486,238)	(37,999,850)
- Taxes paid	-	-
<b>Net Cash flow before extraordinary items</b>	<b>(44,363,693)</b>	<b>(3,742,365)</b>
-Extraordinary & Prior period items	-	-
<b>NET CASH FROM OPERATING ACTIVITIES</b>	<b>(44,363,693)</b>	<b>(3,742,365)</b>
<b>B. CASH FROM INVESTING ACTIVITIES:</b>		
Purchase of Fixed Assets	(3,370,436)	(2,136,633)
Interest Received	1,200,494	2,747,792
Long Term Loans & Advances	(754,003)	(2,740,284)
<b>NET CASH FROM INVESTING ACTIVITIES</b>	<b>(2,923,945)</b>	<b>(2,129,125)</b>
<b>C. CASH FLOW FROM FINANCING ACTIVITIES</b>		
Proceeds from Long Term Borrowings	30,929,398	18,844,667
Long Term Provisions	390,826	1,840,887
<b>NET CASH FROM FINANCING ACTIVITIES</b>	<b>31,320,224</b>	<b>20,685,554</b>
<b>NET INCREASE IN CASH &amp; CASH EQUIVALENTS</b>	<b>(15,967,414)</b>	<b>14,814,066</b>
Opening Cash and cash equivalents	17,553,911	2,739,845
<b>Closing Cash and Cash equivalents</b>	<b>1,586,497</b>	<b>17,553,911</b>

As per our Report of even date  
for **JAYANT & SADASHIV**  
Chartered Accountants  
Firm Reg. No. : 001297S

For and on behalf of the Board of Directors  
**SANGAM HEALTH CARE PRODUCTS LIMITED**

<b>Jayant Palnitkar</b> Partner Membership No: 020851	<b>Bala Gopal Addepalli</b> Managing Director DIN No. 01712903	<b>Padma Ghanakota</b> Director DIN No. 07078176	<b>V. Satish Kumar</b> C.F.O. PAN: ACLPV7670E
---	--	--	---

Place : Hyderabad  
Date : 30.05.2017

## SANGAM HEALTH CARE PRODUCTS LIMITED

### 1 NOTES ANNEXED TO AND FORMING PART OF THE ACCOUNTS

(All amounts are in Indian Rupees except share data and where otherwise stated)

### 2 SHARE CAPITAL

PARTICULARS	31st March 2017	31st March 2016
<b>Authorised Capital</b> 15,000,000 Equity shares of Rs. 10/- each (March 31, 2016, 15,000,000 Shares of Rs.10 each)	150,000,000	150,000,000
<b>Issued, Subscribed &amp; Paid-up capital</b> 14,860,700 Equity shares of Rs. 10/- each fully paid up (March 31, '16, 14,860,700 Equity Shares of Rs.10 each)	148,607,000	148,607,000
<b>Total</b>	<b>148,607,000</b>	<b>148,607,000</b>

- 2.1 The Company has only one class of shares referred to as Equity Shares having a par value of Rs. 10. Each holder of equity shares is entitled to one vote per share.
- 2.2 Rights, preferences and restrictions attached to shares : Equity Shares The Company has one class of equity shares having a par value of Rs. 10 each. Each shareholder is eligible for one vote per share held. In the event of liquidation, the equity shareholders are eligible to receive the remaining assets of the Company after distribution of all preferential amounts, in proportion to their shareholding.
- 2.3 There is no Change in the Shares outstanding at the beginning and at the end of the reporting date and immediately preceding reporting date.
- 2.4 There is a difference of 67,00,000 number in equity shares between equity shares listed with Bombay Stock Exchange (BSE) and equity shares intimated to Registrar of Companies, Hyderabad. The details are as follows :

Particulars	Equity Shares (in Number)
Shares as per ROC (Books of Accounts)	14,860,700
Shares as per BSE	8,160,700
<b>Difference</b>	<b>6,700,000</b>

The company is in the process of rectifying the differential number of equity shares with concerned authorities

- 2.5 The details of shareholder holding more than 5% equity shares :

Name of the Share Holder	31 March 2017		31 March 2016	
	Number	% of holding	Number	% of holding
M/s. Boin Medica Co Ltd	1,240,260	8.35	1,240,260	8.35
Addepalli Balagopal	3,001,000	20.19	3,001,000	20.19
D.V.S.Sharma	2,500,000	16.82	2,500,000	16.82
G.Ramana	2,255,140	15.18	2,255,140	15.18
G.Padma	2,000,000	13.46	2,000,000	13.46



2.6 The reconciliation of the number of equity shares outstanding is set out below;

Particulars	31 March 2017		31 March 2016	
	Number	-	Number	-
Shares outstanding at the beginning of the year	14,860,700	148,607,000	14,860,700	148,607,000
Shares issued during the reporting year	--	--	--	--
Shares outstanding at the end of the year	14,860,700	148,607,000	14,860,700	148,607,700

### 3 RESERVES & SURPLUS

Particulars	31st March 2017	31st March 2016
Revaluation Reserve	77,001,003	77,001,003
<b>Surplus / (deficit) balance in the statement of profit and loss account</b>		
Balance as per last financial statements	(410,536,000)	(395,149,949)
(Loss)/Profit for the year	(68,566,264)	(15,386,051)
<b>TOTAL</b>	<b>(402,101,261)</b>	<b>(333,534,997)</b>

### 4. Long term borrowings

Particulars	Non current portion	
	31 March 2017	31 March '16
<b>Term Loan</b> from banks	250,483,869	217,372,098
<b>Deferred payment liabilities</b> Interest free Sales Tax deferral loan from state government	8,194,476	11,915,073
<b>Unsecured loans</b> Borrowings from Individuals other than Bank (Ref. Note No. 4.2)	50,381,720	48,843,496
<b>Total</b>	<b>309,060,065</b>	<b>278,130,667</b>
The above amount includes		
Secured borrowings	250,483,869	217,372,098
Unsecured borrowings	585,761,196	60,758,569
	309,060,065	278,130,667

#### Note 4.1

Term Loans for Syringe project have been sanctioned by a consortium of State Bank of Hyderabad and State Bank of Mysore

#### Terms of borrowings are as under:

i) First charge over Fixed Assets of the Company for both present and future to the extent of Bank finance by respective banks. ii) Extension of first charge on all the current assets of the Company to SBH and extension of second charge to SBM. iii) Extension of charge on all the collateral securities offered to working capital limits. iv) Extension of Equitable mortgage of Factory Land admeasuring 9 acres and 12 guntas in survey nos.182/b, 175/c at Yellampet village, Medchal Mandal, Ranga Reddy District standing in the name of Company.v) And further guaranteed by promoter directors of the Company in their personal capacity. i) Extension of mortgage of property situated at Flat No: 202, Krishna Appartments,Road no. 4,Banjara Hills, Hyderabad standing in the name of Pagita Leasing Private Limited. vii) Extension of mortgage of property situated at Flat No: 104,

Amarchand Sharma Complex, SP Road, Secunderabad standing in the name of Pagita Leasing Private Limited. viii) Extension of mortgage of property situated at Flat No: 207 admeasuring apprx. 1800 sq.ft. at Amarchand Sharma Complex, SP Road, Secunderabad standing in the name of Sri L.S Patil. ix) Equitable mortgage of house property situated at H No: 6-3-662, Panjagutta, Hyderabad offered by Mrs. Padma and Mrs Ramana, Directors of the Company and Mrs. Vimala (mother of Mrs. Padma and Mrs. Ramana) towards the credit facilities availed by the Company of Rs.37.23 crores (Credit limits already increased from Rs. 31.23 cr to Rs.37.23 cr). x) All secured loans (including working capital loans and term loans) treated as NPA by consortium State Bank of Mysore, Ameerpet Branch and State Bank of Hyderabad, HimmatNagar Branch since there has been no repayments from 2012 onwards for State Bank of Mysore and from December 2016 onwards for State Bank of Hyderabad. Total Default for FY 2016-2017 is Rs. 60 Lakhs to State bank of Mysore and Rs. 276.95 Lakhs to State Bank of Hyderabad.

Term Loans from Banks	Repayment Schedule (Rs.)
Rate of Interest	2016-17
State Bank of Mysore - 15.50%	25,710,000
State Bank of Hyderabad - 13.50%	27,300,000

**Note 4.2** The company has received notice under section 13(2) of SARFAESI Act, 2002 on 15th March, 2017 vide Notice No.NPA/SHCPL/ for recovery of outstanding dues of Rs.33,06,40,808/- for the period till 28th Febraury, 2017 and future interest at agreed contractual rate.

**Note 4.3**

Particulars	Non-Current	
	31 March 2017 (₹)	31 March 2016 (₹)
Ghanakota Ramana	100,000	100,000
Dr. D.V.S. Sharma	2,100,000	2,100,000
A. Balagopal	40,464,899	39,812,500
DVS Krishna Teja	3,907,821	2,950,996
Saswata Gupta	1,904,500	19,40,000
Nandini Gupta	1,904,500	19,40,000

**5. Long Term Provisions**

	Non-Current	
	31 March 2017 (₹)	31 March 2016 (₹)
Provision for employee benefit		
Provision for Gratuity	83,67,279	79,76,453

**6. Short Term borrowings**

Particulars	31 March 2017	31 March 2016
<b>Loans Repayable on Demand</b>		
Cash Credit from Banks (Refer Note 6.1 below)	48,199,037	4,99,77,471
<b>Term Loan</b>		
From Bank	34,800,000	27,300,000
<b>Deferred Payment Liabilities</b>		
Interest free Sales Tax deferral loan from state government	4,156,406	54,61,660
<b>Total</b>	<b>87,155,443</b>	<b>82,739,131</b>
The above amount includes		
Secured borrowings	82,999,037	7,72,77,471
Unsecured borrowings	4,156,406	54,61,660
<b>Total</b>	<b>87,155,443</b>	<b>82,739,131</b>

6.1 Note: State Bank of Hyderabad, Himmatnagar Branch, Secunderabad has provided the Company with Working Capital facilities, which are secured by first charge on the current assets of the Company (both present and future).

## 7. Trade Payables

Particulars	31 March 2017	31 March 2016
<b>Trade Payables</b>		
Dues to Micro and Small Enterprises	-	-
Dues to Others	55,351,058	76,176,237
<b>Total</b>	<b>55,351,058</b>	<b>76,176,237</b>

As at March, 2017 there are not outstanding dues to Micro and Small Enterprises. There are no interests due or outstanding on the same.

## 8. Other current liabilities

Particulars	31 March 2017	31 March 2016
Advances From customers	42,942,364	45,361,835
Salaries and Wages payable	4,498,206	3,014,776
Provident fund payable	11,666,701	8,414,166
ESI contribution payable	741,622	526,189
Interest Payable on statutory dues	3,014,670	-
Other Interest payable	124,407	-
Bonus payable	1,222,020	1,146,114
Electricity Charges Payable	1,030,800	1,970,202
Other Expenses Payable	4,972,713	4,953,519
Security Deposit	240,000	240,000
<b>Taxes Payable</b>		
- Professional tax payable	46,250	13,000
- TDS payable	451,347	198,865
- Excise duty payable	915,042	296,895
- Service Tax Payable	912,104	429,550
<b>Total</b>	<b>72,778,246</b>	<b>66,565,111</b>

## 9. Short Term Provisions

Particulars	31 March 2017	31 March 2016
Provision for employee benefit		
Provision for Gratuity	84,380	598,706
<b>Total</b>	<b>84,380</b>	<b>598,706</b>

**10. Tangible Assets**

Assets	Gross Block			Depreciation			Net Block			
	As at 1-04-2016	Additions	Deletions/ Adjust ments	Total	As at 01-04-2017	For the Year	Deletions/ Adjust ments	Total	As at 31-03-2017	As at 31-03-2016
Land	79,050,000	-	-	-	-	-	-	79,050,000	79,050,000	79,050,000
Buildings	62,032,155	3,097,975	-	65,130,130	21,076,398	1,717,548	-	22,793,946	42,336,184	40,955,757
Plant & Machinery	268,145,876	272,461	-	268,418,337	167,924,050	11,738,499	-	179,662,549	88,755,788	100,221,826
Electrical Installations	19,425,551	-	-	19,425,551	16,048,908	985,027	-	17,033,935	2,391,616	3,376,643
Lab Equipments	8,086,382	-	-	8,086,382	5,737,329	654,114	-	6,391,443	1,694,939	2,349,053
Computers	1,870,406	-	-	1,870,406	1,718,801	86,420	-	1,805,221	65,185	151,605
Office Equipment	1,441,408	-	-	1,441,408	1,424,580	8,735	-	1,433,315	8,093	16,828
Furniture & Fixtures	2,586,171	-	-	2,586,171	2,511,073	26,654	-	2,537,727	48,444	75,098
Vehicles	3,447,411	-	-	3,447,411	3,385,792	-	-	3,385,792	61,619	61,619
<b>Total</b>	<b>446,085,360</b>	<b>3,370,436</b>	<b>-</b>	<b>449,455,796</b>	<b>219,826,930</b>	<b>15,216,997</b>	<b>-</b>	<b>235,043,927</b>	<b>214,411,869</b>	<b>226,258,429</b>
<b>Previous Year</b>	<b>443,948,731</b>	<b>2,136,629</b>	<b>-</b>	<b>446,085,360</b>	<b>204,570,702</b>	<b>15,256,228</b>	<b>-</b>	<b>219,826,930</b>	<b>226,258,430</b>	<b>239,378,029</b>

**11. Long term loans & advances**

Particulars	Non-Current portion	
	31 March 2017	31 March 2016
<b>Unsecured, considered good :</b>		
Security deposits		
Deposits with Government Authorities	4,781,064	3,967,909
Deposits with Others	3,222,022	3,136,401
<b>Other loans and Advances</b>		
Balance with statutory / government authorities		
MAT Credit	5,635,659	5,801,940
TDS Receivable	394,152	372,644
<b>Total</b>	<b>14,032,897</b>	<b>13,278,894</b>

**12. Inventories (valued at lower of cost or net realizable value)**

Particulars	31 March 2017	31 March 2016
Raw Material	3,712,018	3,426,533
Packing Material	4,773,579	4,754,226
Work In Process	36,287,868	56,393,093
Finished Goods	2,834,015	2,860,149
Consumables & Stores and Spares	647,392	1,041,955
<b>Total</b>	<b>48,254,872</b>	<b>68,475,956</b>

**13. Trade receivables**

Particulars	31 March '17	31 March '16
Debts outstanding for a period exceeding six months		
Unsecured		
Considered good	478,576	-
Others Dues		
Unsecured		
Considered good	83,219	1,345,948
<b>Total</b>	<b>561,795</b>	<b>1,345,948</b>

**14. Cash and cash equivalents**

Particulars	Current Portion	
	31 March 2017	31 March 2016
Cash and cash equivalent		
Balance with banks		
In current account	1,562,457	17,535,191
Cash on hand	24,040	18,720
<b>Total</b>	<b>1,586,497</b>	<b>17,553,911</b>

**15. Short Term Loans and Advances**

Particulars	Current Portion	
	31 March 2017	31 March 2016
<b>Unsecured, considered good :</b>		
Balance with statutory / government authorities		
VAT Receivable	240,223	85,379
Interest Receivable	193,571	226,012
Other Balances	20,479	33,776
<b>Total</b>	<b>454,273</b>	<b>345,167</b>

**16. Revenue from operations**

Particulars	31 March 2017	31 March 2016
Sale of Products	255,838,948	251,045,918
Less : Excise Duty	14,201,481	13,884,597
Less : VAT / Sales Tax	5,468,037	5,524,042
<b>Total</b>	<b>236,169,430</b>	<b>231,637,279</b>

Details of Products sold	31 March 2017 Qty. in Nos.	31 March 2016 Qty. in Nos.
1. IV Sets	22,138,454	20,854,530
2. Disposable Syringes	19,119,100	26,578,995
3. Others	2,049,375	3,174,280
<b>Total</b>	<b>43,306,929</b>	<b>50,607,805</b>

**17. Other Income**

Particulars	31 March 2017	31 March 2016
Interest	215,079	291,270
Sundry Balances written off	896,815	2,456,522
Chit Dividend	88,600	-
<b>Total</b>	<b>1,200,494</b>	<b>2,747,792</b>

**18. Cost of material consumed**

Particulars	31 March 2017	31 March 2016
<b>Raw Materials' Consumption</b>		
Opening stock	3,426,533	11,644,722
Add: Purchases	84,538,078	71,963,209
Freight and Octroi on Purchases	1,692,633	1,409,041
	89,657,244	85,016,672
Less : Closing stock	3,712,018	3,426,533
<b>A</b>	85,945,226	81,590,439
<b>Packing Materials' Consumption</b>		
Opening stock	4,754,226	4,982,001
Add: Purchases	18,596,372	15,661,518
Less : Closing stock	4,773,579	4,754,226
<b>B</b>	18,577,019	15,889,293
<b>Consumables' Consumption</b>		
Opening stock	1,041,955	511,934
Add: Purchases	4,648,946	6,410,537
Less : Closing stock	647,392	1,041,955
<b>C</b>	5,043,509	5,880,516
<b>Total (A + B + C)</b>	109,565,754	103,360,248

**18.1 Details of raw material consumed**

Particulars	31 March 2017	31 March 2016
List of major raw material		
S.S Tubes and Cannula	3,572,161	2,744,779
PVC Resin	17,736,952	14,072,789
ABS	19,663,423	14,187,612
DOP	9,118,688	7,366,903
Latex Bulbs	13,215,361	9,495,200
Poly Propylene	10,718,676	11,460,426
Others	11,919,965	22,262,730
Total	85,945,226	81,590,439

**18.2 Value of Imported and domestic raw materials and their percentage to total consumption**

Particulars	%	31 March 2017	%	31 March 2016
Indigenous	100	85,945,226	100	81,590,439
	100	85,945,226	100	81,590,439

**19. Changes in inventories of finished goods and working process**

Particulars	Rs.	31 March 2017	Rs.	31 March 2016
Opening balance				
- Finished goods	2,860,149		1,868,799	
- Work in progress	56,393,093	59,253,242	51,045,556	52,914,355
Closing balance				
- Finished goods	2,834,015		2,860,149	
- Work in progress	36,287,868	39,121,883	56,393,093	59,253,242
<b>TOTAL</b>		<b>20,131,359</b>		<b>(6,338,887)</b>

**20. Employee benefit expenses**

Particulars	31 March 2017	31 March 2016
Salaries, Wages, Bonus etc.	47,279,386	38,572,750
Contribution to P.F, E.S.I and Other Statutory Funds	5,106,007	4,676,555
Workmen and Staff Welfare Expenses	144,599	227,479
Gratuity Expenses	(75,431)	598,706
<b>Total</b>	<b>52,454,561</b>	<b>44,075,490</b>

**21. Finance cost**

Particulars	31 March 2017	31 March 2016
Interest expense	49,746,983	37,898,049
Bank Service Charges	739,255	101,801
<b>Total</b>	<b>50,486,238</b>	<b>37,999,850</b>



**22. Other expenses**

Particulars	31 March 2017	31 March 2016
Audit Fees	250,000	250,000
Consumptions of Store and Spares	2,189,999	2,540,758
Power and Fuel	17,068,161	15,499,866
Factory Maintenance	734,938	525,595
Insurance	502,531	551,298
Rates and Taxes	292,882	527,620
Security Charges	847,934	788,778
Travelling & Conveyance Expenses	683,306	551,192
Job Work Charges	13,167,948	11,243,950
Printing & Stationery	165,417	201,064
Computer Maintenance	5,450	19,040
Telephone Expense	262,685	247,287
Vehicle Maintenance	58,572	71,511
Other General Expenses	1,201,244	178,687
Marketing Expenses	11,006,341	12,666,676
Carriage Outwards	8,925,583	8,831,575
Consultancy and Legal Charges	329,982	497,956
Office Maintenance	222,025	225,340
<b>Total</b>	<b>57,914,998</b>	<b>55,418,193</b>

**23. Remuneration to Auditors**

Particulars	31 March 2017	31 March 2016
As Auditors		
Audit Fee	2,00,000	2,00,000
Tax Audit Fee	50,000	50,000
	250,000	250,000

**24. Related Party disclosures**

<b>A. Name</b>	<b>Description</b>
Sri Sai Healthcare Products	Partnership Concern in which Directors are Interested
Sri Sai Gravure Prints	Partnership Concern in which Directors are Interested
Sri Siri Constructions	Partnership Concern in which Directors are Interested

**Key Management Personnel**

A. Balagopal	Managing Director
V. Satish Kumar	Chief Financial Officer

**B. The following transactions are carried out with the related parties in the course of business**

Particulars	2016-17	2015-16
<b>a. Remuneration to Key Management Personnel</b>		
V. Satish Kumar	780,000	780,000
<b>b. Loans Taken from Directors during the year</b>		
Ghanakota Ramana	-	100,000
Dr. D.V.S. Sharma	-	100,000
A. Balagopal	1,150,000	43,058,705
<b>c. Loans from Shareholders</b>		
Saswata Gupta	-	3,880,000
DVS Teja Krishna	956,825	2,574,356
<b>d. Interest on Loans to Shareholders</b>		
Saswata Gupta	480,000	-
Nandini Gupta	480,000	-
<b>e. Loans Repaid to Directors during the year</b>		
A. Balagopal	497,597	3,246,205
<b>f. Job Work Charges from</b>		
Sri Sai Healthcare Products	2,748,900	1,428,448
Sri Sai Gravure Prints	3,473,723	2,324,385

**C. Balance Outstanding at the end of the Current Year**

Particulars	2016-17	2015-16
Sri Sai Healthcare Products	578,452	-
Sri Sai Gravure Prints	3,060,992	4,521,594
Ghanakota Ramana	100,000	100,000
Dr. D.V.S. Sharma	2,100,000	2,100,000
A. Balagopal	40,464,899	39,812,500
DVS Krishna Teja	3,907,821	2,950,996
Saswata Gupta	1,904,500	1,940,000
Nandini Gupta	1,904,500	1,940,000

**25. Disclosure of Specified Bank Notes**

During the year, the company had Specified Bank Notes (SBNs) or other denomination notes as defined in the MCA Notification, G.S.R 308(E), dated March 31, 2017. The details of SBNs held and transacted during the period from November 8, 2016 to December 30, 2016 the denomination-wise SBNs and other notes as per notification are as follows :

Particulars	Specified Bank Notes (SBNs)	Other Denomination Notes	Total
Closing cash in hand as on 08.11.2016	3,965,000	246,165	4,211,165
(+) Permitted receipts	-	477,000	477,000
(-) Permitted payments	-	679,705	679,705
(-) Amount deposited in Banks	3,965,000	-	3,965,000
<b>Closing cash in hand as on 30.12.2016</b>	<b>-</b>	<b>43,460</b>	<b>43,460</b>

**Note :**

For the purpose of this clause, the term Specified Bank Notes shall have the same meaning provided in the notification of Government of India, in the Ministry of Finance, Department of economic affairs number S.O.3407 ( E ), dated November 8, 2016.

As per our Report of even date  
for **JAYANT & SADASHIV**  
Chartered Accountants  
Firm Reg. No. : 001297S

For and on behalf of the Board of Directors  
**SANGAM HEALTH CARE PRODUCTS LIMITED**

<b>Jayant Palnitkar</b> Partner Membership No: 020851	<b>Bala Gopal Addepalli</b> Managing Director DIN No. 01712903	<b>Padma Ghanakota</b> Director DIN No. 07078176	<b>V. Satish Kumar</b> C.F.O. PAN: ACLPV7670E
---	--	--	---

Place : Hyderabad  
Date : 30.05.2017

## 1. NOTES ANNEXED TO AND FORMING PART OF THE ACCOUNTS COMPANY INFORMATION

**Sangam Health Care Products Limited** is promoted by Group of Doctors, the company manufactures and markets medical devices of highest quality to all parts of India under the brand name "SAFTI". **SANGAM HEALTH CARE PRODUCTS LIMITED** is one of the largest manufacturers of Medical Disposables/ Surgical products, whose products are used in many parts of India.

As a leading manufacturer of Medical Disposables, it contributes to the promotion of health and helps people in maintaining their health standards. The company is convinced that it shall create a new type of enterprise adequate to the changes of the new century, to cope with the conditions aggressively, including enhancing our international competitiveness.

The company is a public limited company incorporated in India and has its registered office at Hyderabad, Telangana, India.

### SIGNIFICANT ACCOUNTING POLICIES

#### a) Basis of preparation of financial statements

These financial statements have been prepared to comply in all material aspects with applicable accounting principles in India, the applicable Accounting Standards prescribed under Section 133 of the Companies Act, 2013 ('Act') read with Rule 7 of the Companies (Accounts) Rules, 2014, the provisions of the Act (to the extent notified) and other accounting principles generally accepted in India, to the extent applicable.

All assets and liabilities have been classified as current or noncurrent as per the Company's normal operating cycle and other criteria set out in the Schedule III to the Act. Based on the nature of products and the time between acquisition of assets for processing and their realisation in cash and cash equivalents, the Company has ascertained its operating cycle as 12 months for the purpose of current/non-current classification of assets and liabilities.

Transactions and balances with values below the rounding off norm adopted by the Company have been reflected as "0.00" in the relevant notes in these financial statements

#### b) Use of estimates

The preparation of financial statements in conformity with Indian GAAP requires the management to make estimates and assumptions that affect the reported balances of assets and liabilities as at the date of the financial statements and reported amounts of income and expense during the year.

Future results could differ due to changes in these estimates and the difference between the actual result and the estimates are recognised in the period in which the results are known / materialise.

**c) Fixed assets**

Tangible assets are stated at acquisition cost, net of accumulated depreciation and accumulated impairment losses, if any. Subsequent expenditures related to an item of tangible asset are added to its book value only if they increase the future benefits from the existing asset beyond its previously assessed standard of performance. Items of tangible assets that have been retired from active use and are held for disposal are stated at the lower of their net book value and net realisable value and are shown separately in the financial statements under "Other current assets". Any expected loss is recognised immediately in the Statement of Profit and Loss. Tangible assets not ready for the intended use on the date of Balance Sheet are disclosed as "Capital work-in-progress". Losses arising from the retirement of, and gains or losses arising from disposal of tangible assets which are carried at cost are recognised in the Statement of Profit and Loss. Depreciation is provided on a pro-rata basis on the straight line method over the useful lives as prescribed under Schedule II to the Companies Act, 2013 with the exception of the following: - plant and equipment is depreciated over 3 to 21 years based on the technical evaluation of useful life done by the management. – Assets costing Rs. 5,000 or less are fully depreciated in the year of purchase.

**d) Impairment of Assets**

Assessment for impairment is done at each Balance Sheet date as to whether there is any indication that an asset (tangible and intangible) may be impaired. For the purpose of assessing impairment, the smallest identifiable group of assets that generates cash inflows from continuing use that are largely independent of the cash inflows from other assets or groups of assets is considered as a cash generating unit. If any such indication exists, an estimate of the recoverable amount of the individual asset/cash generating unit is made. Assets whose carrying value exceeds their recoverable amount are written down to the recoverable amount by recognising the impairment loss as an expense in the Statement of Profit and Loss. Recoverable amount is higher of an asset's or cash generating unit's net selling price and its value in use. Value in use is the present value of estimated future cash flows expected to arise from the continuing use of an asset and from its disposal at the end of its useful life. Assessment is also done at each Balance Sheet date as to whether there is any indication that an impairment loss recognised for an asset in prior accounting periods may no longer exist or may have decreased.

**e) Inventories**

Inventories are valued at the lower of cost and net realisable value. Cost is computed on a weighted average basis. The net realisable value is the estimated selling price in the ordinary course of business less the estimated costs of completion and estimated costs necessary to make the sale. Finished goods and work-in-progress include all costs of purchases, conversion costs and other costs incurred in bringing the inventories to their present location and condition

**f) Revenue Recognition**

Revenue from sale of goods is recognised when all the significant risks and rewards of ownership in the goods are transferred to the buyer as per the terms of the contract, the Company retains no effective control of the goods transferred to a degree usually associated with ownership and no significant uncertainty exists regarding the amount of the consideration that will be derived from the sale of goods. Sales are recognised net of trade discounts, rebates, sales taxes and excise duties (on goods manufactured and outsourced).

**g) Foreign Exchange transactions**

Foreign currency transactions are accounted for at the exchange rates prevailing at the date of the transaction. Gains and losses resulting from the settlement of such transactions and from the translation of monetary assets and liabilities denominated in foreign currencies are recognised in the Statement of Profit and Loss.

**h) Taxes on Income**

- No Provision for Income tax and Minimum alternate tax is made in the current year in view of computation of income and calculation as per Minimum alternate tax resulting in loss as per the provisions of Income Tax Act.
- In view of the unabsorbed depreciation and carried forward losses available for set off under Income Tax Act, 1961, deferred tax for the year is not recognised in the accounts on prudent basis.

**26. Provisions and Contingent Liabilities**

A provision is recognized if, as a result of past event, the company has a present obligation that is reasonably estimable, and it is probable that an outflow of economic benefits will be required to settle the obligation. Provisions are determined by the best estimate of the outflow of economic benefits required to settle the obligation at the reporting date. Where no reliable estimate can be made, a disclosure is made below as contingent liability.

	As on 31.03.17	As on 31.03.16
Amount in respect of Interest on Term Loan	75.31	Nil
Amount in respect of Provident Fund as Interest & Penalty	5.10	5.10

**27 Retirement Benefits**

Provident Fund contributions are provided and charged to the Profit and Loss Account during the financial year.

Provision for Gratuity is made on the basis of actuarial valuation in accordance with AS-15 "Employee Benefits"

Leave Encashment benefit is accounted on payment basis.

<b>Profit &amp; Loss Account</b>		
	<b>2016-17</b>	<b>2015-16</b>
Current Service Cost	2,15,540	2,19,079
Interest Cost on benefit obligation	6,86,013	6,69,727
Net Actuarial (gain). Loss recognized in the year	(9,76,984)	(2,90,100)
<b>Net Benefit expense</b>	<b>(75,431)</b>	<b>5,98,706</b>

<b>Balance Sheet</b>		
Details of provision for Gratuity		
Change in the present value of the defined benefit obligation are as follows:		
Opening defined benefit obligation	85,75,159	83,71,585
Interest cost	6,86,013	6,69,727
Current services cost	2,15,540	2,19,079
Benefits paid	(48,069)	(3,95,132)
Actuarial (gains)/losses on obligation	(9,76,984)	(2,90,100)
closing defined benefit obligation	<b>84,51,659</b>	<b>85,75,159</b>

Retirement age	58 years
Future Salary Rise	4%
Rate of Discounting	8%
Attrition Rate	1%
Mortality Table	LIC (2006-2008)

28. Details of Opening Stock, Production, Turnover and Closing Stock of Finished Goods for the year 2016-17(2015-16)								
S. No.	Description	Opening Stock		Production	Sales		Closing	
		Qty (Numbers)	Value (₹)	Qty (Numbers)	Qty (Numbers)	Value (₹)	Qty (Numbers)	Value (₹)
1	IV Sets	89,500	1,489,388	22,161,507	22,138,454	212,109,927	112,553	1,776,820
		(60,438)	(1,415,825)	(208,833,592)	(20,854,530)	(196,543,107)	(89,500)	(1,489,388)
2	Syringes	391,800	654,641	18,916,500	19,119,100	29,202,325	189,200	252,596
		(143,320)	(220,822)	(26,827,475)	(26,578,995)	(39,971,705)	(391,800)	(654,641)
3	Others	120,308	716,120	2,819,487	2,049,375	14,526,696	890,420	804,599
		(40,000)	(232,152)	(3,254,588)	(3,174,280)	(14,726,430)	(120,308)	(716,120)

## 29. Details of Raw Material Consumed

Description	UOM	Raw material		Raw material	
		31.03.2017	31.03.2017	31.03.2016	31.03.2016
		Qty (Numbers)	Value (₹ in lakhs)	Qty (Numbers)	Value (₹ in lakhs)
ABS	Kgs	1,18,213	196.63	95,675	142.00
D.O.P	Kgs	1,00,330	91.18	91,800	73.67
LATEX BULB	Nos.	2,08,60,000	132.15	1,79,50,000	94.95
POLYPROPYLENE	Kgs	12,025	107.18	1,40,000	114.60
CANNUALE / S.S.TUBE	Mtrs.	17,93,100	35.72	18,80,000	27.45
PVC	Kgs	2,36,319	177.36	2,07,300	140.73
OTHERS			119.19		222.5
<b>TOTAL</b>			<b>859.45</b>		<b>815.90</b>

**30** The details of micro and small enterprises units to whom the Company owes a sum exceeding Rupees one lakh which is outstanding for more than 30 days as on the date of Balance sheet : NIL

**31 Earnings per share**

Basic earnings per share is calculated by dividing the net loss for the year attributable to equity shareholders by the weighted average number of equity shares outstanding during the period. The weighted average number of equity shares outstanding during the period and for all periods presented is adjusted for events, such as bonus shares, other than the conversion of potential equity shares that have changed the number of equity shares outstanding, without a corresponding change in resources. For the purpose of calculating diluted earnings per share, the net loss for the period attributable to equity shareholders and the weighted average number of shares outstanding during the period is adjusted for the effects of all dilutive potential equity shares

**32 Cash and Cash Equivalents**

In the cash flow statement, cash and cash equivalents include cash in hand, term deposits with banks and other short-term highly liquid investments with original maturities of three months or less. Cash and cash equivalents comprise cash and cash-on-deposit with banks.

**33 Cash Flow Statements**

Cash flows are reported using the indirect method, where by profit /(Loss) before tax is adjusted for the effects of transactions of a non-cash nature, any deferrals or accruals of past or future operating cash receipts or payments and item of income or expenses associated with investing or financing cash flows. The cash flows from operating, investing and financing activities of the company are segregated.

**34** Balances of certain debtors, creditors, loans and advances, unsecured loans, receivables and payables are subject to confirmation and reconciliation and consequential adjustment in the accounts.

**35** Previous year figures have been regrouped / rearranged wherever necessary to confirm to the current year's grouping / classification.

**36** Schedules '2 to 36' annexed to the Balance Sheet and Profit and Loss Statement form part of accounts.

As per our Report of even date  
for **JAYANT & SADASHIV**  
Chartered Accountants  
Firm Reg. No. : 001297S

For and on behalf of the Board of Directors  
**SANGAM HEALTH CARE PRODUCTS LIMITED**

<b>Jayant Palnitkar</b> Partner Membership No: 020851	<b>Bala Gopal Addepalli</b> Managing Director DIN No. 01712903	<b>Padma Ghanakota</b> Director DIN No. 07078176	<b>V. Satish Kumar</b> C.F.O. PAN: ACLPV7670E
---	--	--	---

Place : Hyderabad  
Date : 30.05.2017



**SANGAM HEALTH CARE PRODUCTS LIMITED**

**23<sup>rd</sup> ANNUAL GENERAL MEETING**

**205 & 206, AMARCHAND SHARMA COMPLEX  
S P ROAD, SECUNDERABAD – 500003**

**ATTENDANCE SLIP**

<b>Date</b>	<b>Venue</b>	<b>Time</b>
29/09/2017	Flat No. 205 & 206, Amarchand Sharma Complex, S.P. Road, Secunderabad - 500003.	3.00 p.m.

**DP ID :** \_\_\_\_\_

**Folio No. / Clients ID :** \_\_\_\_\_

**No. of Shares :** \_\_\_\_\_

**Name and Address of the First / Sole Shareholder :**

\_\_\_\_\_  
\_\_\_\_\_

I certify that I am a registered shareholder of the Company; holding above mentioned shares in the Company, and hereby record my presence at the 23<sup>rd</sup> Annual General Meeting of the Company.

**Member's/Proxy signature**

- Note:
- Only Member / Proxy can attend the Meeting. No minors would be allowed at the Meeting.
  - Member/Proxy holder who wish to attend the meeting must bring the Admission Slip and hand over at the entrance duly signed.
  - Member/Proxy should bring his/her copy of the Annual Report for reference at the Meeting.

**23<sup>rd</sup> Annual General Meeting**  
**SANGAM HEALTH CARE PRODUCTS LIMITED**

CIN : L24230TG1993PLC016731  
205 & 206, Amarchand Sharma Complex, S P Road, Secunderabad – 3.  
Tel : 040 27719551. Email: [sangamlisting@gmail.com](mailto:sangamlisting@gmail.com).

**PROXY FORM**

**[Pursuant to section 105(6) of the Companies Act, 2013 and rule 19(3) of the Companies (Management and Administration) Rules, 2014]**

**Name of the member (s):** .....

**Registered address:** .....

**E-mail Id:** .....

**Folio No/ Client Id:** .....

**DP ID:** .....


I/We, being the member (s) of ..... shares of the above named company, hereby appoint

1. Name: .....  
Address: .....  
E-mail Id: .....  
Signature ....., or failing him
2. Name: .....  
Address: .....  
E-mail Id: .....  
Signature ....., or failing him
3. Name: .....  
Address: .....  
E-mail Id: .....  
Signature ....., or failing him

as my/our proxy to attend and vote (on a poll) for me/us and on my/our behalf at the 23rd Annual general meeting of the company, to be held on the 29th day of September 2017 at 3.00 p.m. at Regd. Office : 205 & 206, Amarchand Sharma Complex, S P Road, Secunderabad – 3. and at any adjournment thereof in respect of such resolutions as are indicated below:

S.No.	Particulars	For	Against
	<b>ORDINARY BUSINESS:</b>		
1.	To receive, consider and adopt the Audited Financial Statements for the financial year ended 31st March, 2017 and the Reports of the Directors and Auditors thereon		
2.	To re-appoint Mrs. Padma Ghanakota (DIN : 07078176), who retires by rotation, and being eligible offers herself for the re-appointment		
3.	To ratify the continuation of the Statutory Auditors M/s. Jayant & Sadashiv		

Signed this..... day of..... 2017



\_\_\_\_\_  
Signature of shareholder

\_\_\_\_\_  
Signature of Proxy holder(s)

Note: This form of proxy in order to be effective should be duly completed and deposited at the Registered Office of the Company, not less than 48 hours before the commencement of the Meeting.

**NOTES:**

- a. Only Member/Proxy can attend the Meeting. No minors would be allowed at the Meeting.
- b. Member/Proxy who wish to attend the Meeting must bring this attendance slip to the Meeting and hand over at the entrance duly filled in and signed.
- c. Member/Proxy should bring his/her copy of the Annual Report for reference at the Meeting.

**BOOK POST**

**IF UNDELIVERED, PLEASE RETURN TO :**

**SANGAM HEALTH CARE PRODUCTS LTD.**

205 & 206, Amar Chand Sharma Complex,

S.P. Road, Secunderabad - 500 003.